CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | boronic acids |
|
Accession: | CHEBI:38269
|
browse the term
|
Definition: | Compounds having the structure RB(OH)2. |
Synonyms: | related_synonym: | Formula=BH2O2R; SMILES=OB(O)[*] |
| xref: | Wikipedia:Boronic_acid |
|
|
|
G |
Nphs1 |
NPHS1 adhesion molecule, nephrin |
increases expression |
ISO |
BD4 increases expression of Nphs1 mRNA in podocytes |
RGD |
PMID:22125642 |
RGD:40902998 |
NCBI chr 1:85,720,812...85,749,079
Ensembl chr 1:85,720,812...85,749,078
|
|
G |
Synpo |
synaptopodin |
increases expression |
ISO |
BD4 increases expression of Synpo mRNA in podocytes |
RGD |
PMID:22125642 |
RGD:40902998 |
NCBI chr18:54,048,299...54,106,388
Ensembl chr18:54,026,152...54,102,126
|
|
|
G |
Abca2 |
ATP binding cassette subfamily A member 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ABCA2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:8,244,515...8,264,545
Ensembl chr 3:8,244,639...8,264,537
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions decreases activity decreases expression |
ISO |
[Bortezomib co-treated with Doxorubicin] results in decreased expression of ABCB1 protein; ATP2A1 protein affects the reaction [Bortezomib results in decreased expression of ABCB1]; Bortezomib inhibits the reaction [CERS2 protein affects the expression of ABCB1 protein]; Bortezomib inhibits the reaction [CERS6 protein affects the expression of ABCB1 protein]; Bortezomib promotes the reaction [Chloroquine results in decreased expression of ABCB1 mRNA]; Bortezomib promotes the reaction [Chloroquine results in decreased expression of and results in increased nitrosation of ABCB1 protein]; Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1 protein; Chloroquine promotes the reaction [Bortezomib results in decreased expression of ABCB1 mRNA]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1 protein] Bortezomib results in decreased activity of ABCB1 protein Bortezomib results in decreased expression of ABCB1; Bortezomib results in decreased expression of ABCB1 mRNA; Bortezomib results in decreased expression of ABCB1 protein Bortezomib results in decreased expression of ABCB1A mRNA [Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein; Bortezomib promotes the reaction [Chloroquine results in decreased expression of ABCB1A mRNA]; Bortezomib promotes the reaction [Chloroquine results in decreased expression of and results in increased nitrosation of ABCB1A protein]; Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1A protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of ABCB1A mRNA]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1A protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]] |
CTD |
PMID:25576094 PMID:30482226 PMID:33775688 PMID:34915026 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
decreases expression multiple interactions |
ISO |
Bortezomib results in decreased expression of ABCC1 mRNA [Bortezomib co-treated with Doxorubicin] results in decreased expression of ABCC1 protein |
CTD |
PMID:20977926 PMID:33775688 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases expression |
ISO |
Bortezomib results in increased expression of ABCC2 mRNA |
CTD |
PMID:21215737 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ABCC4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Abhd16a |
abhydrolase domain containing 16A, phospholipase |
increases expression |
ISO |
Bortezomib results in increased expression of ABHD16A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr20:3,719,089...3,733,952
Ensembl chr20:3,719,091...3,733,927
|
|
G |
Abhd2 |
abhydrolase domain containing 2, acylglycerol lipase |
increases expression |
ISO |
Bortezomib results in increased expression of ABHD2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:133,217,403...133,298,564
Ensembl chr 1:133,217,375...133,299,061
|
|
G |
Abi1 |
abl-interactor 1 |
increases expression |
ISO |
Bortezomib results in increased expression of ABI1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:85,098,837...85,179,829
Ensembl chr17:85,098,550...85,179,792
|
|
G |
Abl1 |
ABL proto-oncogene 1, non-receptor tyrosine kinase |
multiple interactions |
ISO |
[alvocidib co-treated with Bortezomib co-treated with ABL1 protein] results in decreased phosphorylation of LYN protein; [alvocidib co-treated with Bortezomib co-treated with ABL1] results in decreased phosphorylation of CRKL protein; [alvocidib co-treated with Bortezomib] results in decreased expression of ABL1 protein; [Arsenic Trioxide co-treated with Bortezomib] results in decreased expression of ABL1 protein; [Bortezomib co-treated with N,N-dimethylsphingosine] results in decreased expression of ABL1 protein; Bortezomib promotes the reaction [Dichlororibofuranosylbenzimidazole results in decreased expression of ABL1 protein] |
CTD |
PMID:15039284 PMID:17495969 PMID:21195056 |
|
NCBI chr 3:14,979,853...15,083,065
Ensembl chr 3:14,979,853...15,083,065
|
|
G |
Ace |
angiotensin I converting enzyme |
multiple interactions |
ISO |
[Butyrates co-treated with Bortezomib] results in increased activity of ACE protein mutant form |
CTD |
PMID:20454656 |
|
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Acot7 |
acyl-CoA thioesterase 7 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ACOT7 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:162,686,562...162,779,309
Ensembl chr 5:162,684,645...162,779,309
|
|
G |
Adam10 |
ADAM metallopeptidase domain 10 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ADAM10 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 8:71,346,008...71,477,889
Ensembl chr 8:71,345,837...71,477,889
|
|
G |
Adm |
adrenomedullin |
multiple interactions decreases expression |
ISO |
Bortezomib inhibits the reaction [arsenic trioxide results in decreased expression of ADM mRNA] Bortezomib results in decreased expression of ADM mRNA |
CTD |
PMID:20471514 |
|
NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654
|
|
G |
Aff1 |
ALF transcription elongation factor 1 |
increases expression |
ISO |
Bortezomib results in increased expression of AFF1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr14:5,861,188...6,024,196
Ensembl chr14:5,863,961...6,024,729
|
|
G |
Aff4 |
ALF transcription elongation factor 4 |
increases expression |
ISO |
Bortezomib results in increased expression of AFF4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:37,498,825...37,579,751
Ensembl chr10:37,498,825...37,579,751
|
|
G |
Afg2a |
AFG2 AAA ATPase homolog A |
increases expression |
ISO |
Bortezomib results in increased expression of AFG2A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:120,306,417...120,497,707
Ensembl chr 2:120,306,412...120,497,705
|
|
G |
Ager |
advanced glycosylation end product-specific receptor |
multiple interactions increases expression |
EXP |
Berberine inhibits the reaction [Bortezomib results in increased expression of AGER mRNA] |
CTD |
PMID:35121005 |
|
NCBI chr20:4,148,150...4,151,361
Ensembl chr20:4,147,890...4,151,078
|
|
G |
Agk |
acylglycerol kinase |
decreases expression |
ISO |
Bortezomib results in decreased expression of AGK mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:69,114,850...69,193,989
Ensembl chr 4:69,114,269...69,193,934
|
|
G |
Agrn |
agrin |
decreases expression |
ISO |
Bortezomib results in decreased expression of AGRN mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:166,749,306...166,782,212
Ensembl chr 5:166,749,310...166,786,003
|
|
G |
Agtpbp1 |
ATP/GTP binding carboxypeptidase 1 |
increases expression |
ISO |
Bortezomib results in increased expression of AGTPBP1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:5,120,540...5,238,874
Ensembl chr17:5,120,609...5,238,869
|
|
G |
Agtrap |
angiotensin II receptor-associated protein |
decreases expression |
ISO |
Bortezomib results in decreased expression of AGTRAP mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:158,507,427...158,519,036
Ensembl chr 5:158,508,749...158,519,036
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
affects localization multiple interactions |
ISO |
Bortezomib affects the localization of AIFM1 protein [Bortezomib co-treated with Butyrates] affects the localization of AIFM1 protein; [Bortezomib co-treated with vorinostat] affects the localization of AIFM1 protein |
CTD |
PMID:12893773 PMID:16024631 |
|
NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256
|
|
G |
Aifm2 |
AIF family member 2 |
increases expression |
ISO |
Bortezomib results in increased expression of AIFM2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr20:29,654,283...29,679,239
Ensembl chr20:29,652,927...29,679,236
|
|
G |
Aim2 |
absent in melanoma 2 |
increases expression |
ISO |
Bortezomib results in increased expression of AIM2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr13:85,865,206...85,906,996
Ensembl chr13:85,866,284...85,906,975
|
|
G |
Airim |
AFG2 interacting ribosome maturation factor |
increases expression |
ISO |
Bortezomib results in increased expression of AIRIM mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:137,198,688...137,205,912
Ensembl chr 5:137,198,720...137,204,026
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B1 |
increases expression |
ISO |
Bortezomib results in increased expression of AKR1B1 mRNA; Bortezomib results in increased expression of AKR1B1 protein |
CTD |
PMID:21215737 |
|
NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157
|
|
G |
Akr1b10 |
aldo-keto reductase family 1 member B10 |
increases expression |
ISO |
Bortezomib results in increased expression of AKR1B10 mRNA; Bortezomib results in increased expression of AKR1B10 protein |
CTD |
PMID:21215737 |
|
NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852
|
|
G |
Akr1c1 |
aldo-keto reductase family 1, member C1 |
multiple interactions increases expression |
ISO |
[Arsenic Trioxide co-treated with Bortezomib] results in increased expression of AKR1C1 mRNA Bortezomib results in increased expression of AKR1C1 mRNA |
CTD |
PMID:21215737 PMID:25913414 |
|
NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326
|
|
G |
Akr1c2 |
aldo-keto reductase family 1, member C2 |
affects expression |
ISO |
Bortezomib affects the expression of AKR1C2 mRNA |
CTD |
PMID:21215737 |
|
NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
increases expression |
ISO |
Bortezomib results in increased expression of AKR1C3 mRNA |
CTD |
PMID:21215737 |
|
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
|
|
G |
Akr7a2 |
aldo-keto reductase family 7, member A2 |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of AKR7A2 mRNA |
CTD |
PMID:25522274 |
|
NCBI chr 5:151,552,375...151,560,914
Ensembl chr 5:151,552,343...151,560,909
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases activity decreases expression |
ISO |
[alvocidib co-treated with Bortezomib] results in decreased expression of AKT1 protein modified form; [Bortezomib co-treated with lapatinib] results in decreased phosphorylation of AKT1 protein; [Bortezomib co-treated with lonafarnib] results in decreased expression of AKT1 protein; [Bortezomib co-treated with lonafarnib] results in decreased expression of AKT1 protein modified form; [Bortezomib co-treated with panobinostat] results in decreased activity of AKT1 protein; [Bortezomib co-treated with sorafenib] results in decreased phosphorylation of AKT1 protein; [Bortezomib results in decreased activity of CBL protein] promotes the reaction [arsenic trioxide results in increased activity of AKT1 protein]; [geldanamycin co-treated with Bortezomib] results in decreased expression of AKT1 protein; [vorinostat co-treated with Bortezomib] results in decreased phosphorylation of and results in decreased expression of AKT1 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP3 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP9 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of PARP1 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein]; AKT1 protein results in decreased susceptibility to [Bortezomib co-treated with sorafenib]; Bortezomib inhibits the reaction [TNFSF10 protein results in increased activity of AKT1 protein]; Okadaic Acid inhibits the reaction [Bortezomib results in decreased expression of AKT1 protein modified form] Bortezomib results in decreased activity of AKT1 protein |
CTD |
PMID:15039284 PMID:15781649 PMID:16118318 PMID:16985072 PMID:18445700 PMID:18701494 PMID:19261616 PMID:19457607 PMID:20701607 PMID:21472287 More...
|
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alad |
aminolevulinate dehydratase |
decreases activity multiple interactions |
ISO |
Bortezomib results in decreased activity of ALAD protein Curcumin inhibits the reaction [Bortezomib results in decreased activity of ALAD protein] |
CTD |
PMID:25352650 |
|
NCBI chr 5:75,961,993...75,972,334
Ensembl chr 5:75,961,993...75,972,474
|
|
G |
Aldh18a1 |
aldehyde dehydrogenase 18 family, member A1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ALDH18A1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:239,375,657...239,407,956
Ensembl chr 1:239,375,669...239,407,890
|
|
G |
Aldh5a1 |
aldehyde dehydrogenase 5 family, member A1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ALDH5A1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:40,132,339...40,158,677
Ensembl chr17:40,130,883...40,158,677
|
|
G |
Aldh6a1 |
aldehyde dehydrogenase 6 family, member A1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ALDH6A1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:104,077,975...104,098,636
Ensembl chr 6:104,077,979...104,098,656
|
|
G |
Alox12 |
arachidonate 12-lipoxygenase, 12S type |
increases response to substance |
ISO |
ALOX12 gene SNP results in increased susceptibility to Bortezomib |
CTD |
PMID:20864405 |
|
NCBI chr10:54,958,263...54,970,542
Ensembl chr10:54,958,271...54,970,542
|
|
G |
Anapc11 |
anaphase promoting complex subunit 11 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ANAPC11 mRNA |
CTD |
PMID:17659339 |
|
NCBI chr10:105,875,209...105,886,307
|
|
G |
Anapc5 |
anaphase-promoting complex subunit 5 |
decreases expression increases expression |
ISO |
Bortezomib results in decreased expression of ANAPC5 mRNA Bortezomib results in increased expression of ANAPC5 mRNA |
CTD |
PMID:17895889 PMID:20977926 |
|
NCBI chr12:33,748,709...33,781,709
Ensembl chr12:33,748,735...33,781,781
|
|
G |
Ankrd9 |
ankyrin repeat domain 9 |
increases expression |
ISO |
Bortezomib results in increased expression of ANKRD9 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:130,001,914...130,008,792
Ensembl chr 6:129,998,486...130,008,923
|
|
G |
Ano10 |
anoctamin 10 |
increases expression |
ISO |
Bortezomib results in increased expression of ANO10 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 8:121,841,664...121,960,739
Ensembl chr 8:121,841,665...121,962,670
|
|
G |
Ap1s1 |
adaptor related protein complex 1 subunit sigma 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of AP1S1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr12:19,625,267...19,635,792
Ensembl chr12:19,625,332...19,756,713
|
|
G |
Ap2a1 |
adaptor related protein complex 2 subunit alpha 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of AP2A1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:95,384,306...95,414,170
Ensembl chr 1:95,384,309...95,414,147
|
|
G |
Apobr |
apolipoprotein B receptor |
decreases expression |
ISO |
Bortezomib results in decreased expression of APOBR mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:181,169,019...181,173,206
Ensembl chr 1:181,168,916...181,173,528
|
|
G |
Apol9a |
apolipoprotein L9a |
decreases expression |
ISO |
Bortezomib results in decreased expression of APOL4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:109,140,871...109,149,799
Ensembl chr 7:109,140,871...109,147,649
|
|
G |
Apool |
apolipoprotein O-like |
increases expression |
ISO |
Bortezomib results in increased expression of APOOL mRNA |
CTD |
PMID:20977926 |
|
NCBI chr X:77,377,723...77,443,672
Ensembl chr X:77,377,781...77,443,900
|
|
G |
Aqp3 |
aquaporin 3 (Gill blood group) |
increases expression |
ISO |
Bortezomib results in increased expression of AQP3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
Bortezomib binds to and results in decreased activity of AR protein; Bortezomib inhibits the reaction [Metribolone results in increased activity of AR protein] |
CTD |
PMID:25752796 PMID:30818834 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Arf6 |
ARF GTPase 6 |
increases expression |
ISO |
Bortezomib results in increased expression of ARF6 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:87,853,742...87,854,890
Ensembl chr 6:87,840,142...87,874,114
|
|
G |
Arfgap1 |
ARF GTPase activating protein 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ARFGAP1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:168,084,560...168,099,948
Ensembl chr 3:168,084,614...168,099,933
|
|
G |
Arhgap1 |
Rho GTPase activating protein 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ARHGAP1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:77,621,377...77,643,400
Ensembl chr 3:77,620,655...77,643,396
|
|
G |
Arhgdia |
Rho GDP dissociation inhibitor alpha |
decreases expression |
ISO |
Bortezomib results in decreased expression of ARHGDIA mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:105,854,526...105,858,020
Ensembl chr10:105,854,533...105,858,023
|
|
G |
Arid3b |
AT-rich interaction domain 3B |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ARID3B mRNA |
CTD |
PMID:25522274 |
|
NCBI chr 8:58,193,268...58,240,901
Ensembl chr 8:58,193,418...58,238,318
|
|
G |
Arl4c |
ARF like GTPase 4C |
decreases expression |
ISO |
Bortezomib results in decreased expression of ARL4C mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 9:89,300,335...89,303,770
Ensembl chr 9:89,298,005...89,304,513
|
|
G |
Arl8a |
ARF like GTPase 8A |
increases expression |
ISO |
Bortezomib results in increased expression of ARL8A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr13:46,585,845...46,594,851
Ensembl chr13:46,585,845...46,594,851
|
|
G |
Arln |
allregulin |
decreases expression |
ISO |
Bortezomib results in decreased expression of ARLN mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:211,055,925...211,057,685
Ensembl chr 2:211,055,911...211,057,681
|
|
G |
Arrb1 |
arrestin, beta 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ARRB1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:153,837,964...153,912,111
Ensembl chr 1:153,838,078...153,904,061
|
|
G |
Asap1 |
ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ASAP1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:95,786,130...96,093,111
Ensembl chr 7:95,787,818...96,092,754
|
|
G |
Ate1 |
arginyltransferase 1 |
increases expression |
ISO |
Bortezomib results in increased expression of ATE1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:184,961,548...185,081,112
Ensembl chr 1:184,963,562...185,080,908
|
|
G |
Atf2 |
activating transcription factor 2 |
multiple interactions increases expression increases phosphorylation |
ISO |
pyrazolanthrone inhibits the reaction [Bortezomib results in increased phosphorylation of ATF2 protein] Bortezomib results in increased expression of ATF2 mRNA |
CTD |
PMID:12393500 PMID:20977926 |
|
NCBI chr 3:58,718,323...58,795,280
Ensembl chr 3:58,718,332...58,795,236
|
|
G |
Atf3 |
activating transcription factor 3 |
increases response to substance multiple interactions increases expression |
ISO EXP |
ATF3 results in increased susceptibility to Bortezomib [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ATF3 mRNA; ATF3 mutant form promotes the reaction [Bortezomib results in increased expression of PMAIP1 mRNA] Bortezomib results in increased expression of ATF3; Bortezomib results in increased expression of ATF3 mRNA; Bortezomib results in increased expression of ATF3 protein |
CTD |
PMID:17898295 PMID:20022965 PMID:20830808 PMID:21762082 PMID:25522274 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atf4 |
activating transcription factor 4 |
multiple interactions decreases response to substance increases expression |
ISO |
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Bortezomib results in increased expression of ATF4 protein]; ATF4 mutant form inhibits the reaction [Bortezomib results in increased expression of PMAIP1 mRNA]; ATF4 mutant form inhibits the reaction [Bortezomib results in increased expression of PMAIP1 protein]; Bortezomib promotes the reaction [ATF4 protein binds to PMAIP1 promoter]; Dactinomycin inhibits the reaction [Bortezomib results in increased expression of ATF4 mRNA]; Dactinomycin inhibits the reaction [Bortezomib results in increased expression of ATF4 protein]; NUPR1 mutant form promotes the reaction [Bortezomib results in increased expression of ATF4 mRNA] ATF4 results in decreased susceptibility to Bortezomib Bortezomib results in increased expression of ATF4 mRNA; Bortezomib results in increased expression of ATF4 protein |
CTD |
PMID:15509775 PMID:16928686 PMID:20022965 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atf5 |
activating transcription factor 5 |
increases expression |
ISO |
Bortezomib results in increased expression of ATF5 mRNA |
CTD |
PMID:17898295 |
|
NCBI chr 1:95,295,602...95,299,755
Ensembl chr 1:95,295,610...95,299,707
|
|
G |
Atg5 |
autophagy related 5 |
multiple interactions |
ISO |
ATG5 gene mutant form inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; ATG5 gene mutant form inhibits the reaction [HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]] |
CTD |
PMID:22842577 |
|
NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209
|
|
G |
Atm |
ATM serine/threonine kinase |
multiple interactions increases cleavage |
ISO |
[CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of ATM protein]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of ATM protein] |
CTD |
PMID:12393500 |
|
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Atp1a3 |
ATPase Na+/K+ transporting subunit alpha 3 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ATP1A3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:80,572,790...80,601,936
Ensembl chr 1:80,572,796...80,601,918
|
|
G |
Atp2a1 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 1 |
multiple interactions affects response to substance |
ISO |
ATP2A1 protein affects the reaction [Bortezomib results in decreased expression of ABCB1] ATP2A1 protein affects the susceptibility to Bortezomib |
CTD |
PMID:25576094 |
|
NCBI chr 1:181,026,606...181,044,859
Ensembl chr 1:181,026,608...181,044,838
|
|
G |
Atp6v0e1 |
ATPase H+ transporting V0 subunit e1 |
increases expression |
ISO |
Bortezomib results in increased expression of ATP6V0E1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:16,479,656...16,502,732
Ensembl chr10:16,479,567...16,524,434
|
|
G |
B2m |
beta-2 microglobulin |
decreases expression |
ISO |
Bortezomib results in decreased expression of B2M protein |
CTD |
PMID:17204182 |
|
NCBI chr 3:109,095,740...109,101,764
Ensembl chr 3:109,095,729...109,101,766
|
|
G |
B3gnt2 |
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of B3GNT2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr14:96,808,473...96,833,674
Ensembl chr14:96,806,664...96,835,273
|
|
G |
B4galt6 |
beta-1,4-galactosyltransferase 6 |
increases expression |
ISO |
Bortezomib results in increased expression of B4GALT6 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr18:11,958,382...12,015,247
Ensembl chr18:11,958,390...12,015,247
|
|
G |
Bag3 |
BAG cochaperone 3 |
increases expression |
ISO |
Bortezomib results in increased expression of BAG3 mRNA |
CTD |
PMID:15509775 PMID:17659339 PMID:20471514 |
|
NCBI chr 1:183,103,038...183,126,862
Ensembl chr 1:183,102,871...183,126,858
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
multiple interactions increases expression |
ISO |
[nutlin 3 co-treated with Bortezomib] results in increased activity of BAK1 protein; BAK1 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] Bortezomib results in increased expression of BAK1 protein BAK1 protein results in increased susceptibility to [Bortezomib co-treated with TNFSF10 protein] |
CTD |
PMID:12902978 PMID:17326159 PMID:20850924 |
|
NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
|
|
G |
Bard1 |
BRCA1 associated RING domain 1 |
increases response to substance |
ISO |
BARD1 mutant form results in increased susceptibility to Bortezomib |
CTD |
PMID:25522274 |
|
NCBI chr 9:72,616,070...72,694,553
Ensembl chr 9:72,623,155...72,694,265
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
ISO |
[Bortezomib co-treated with arsenic trioxide] affects the expression of BAX protein; [nutlin 3 co-treated with Bortezomib] results in increased activity of BAX protein; BAX results in increased susceptibility to [Bortezomib co-treated with panobinostat]; Bortezomib inhibits the reaction [BAX mutant form inhibits the reaction [TNFSF10 protein results in increased localization of DIABLO protein]] Bortezomib results in increased expression of BAX protein |
CTD |
PMID:12902978 PMID:18445700 PMID:18718063 PMID:20383943 PMID:20850924 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
increases expression |
ISO |
Bortezomib results in increased expression of BBC3 mRNA; Bortezomib results in increased expression of BBC3 protein |
CTD |
PMID:17898295 PMID:20051518 |
|
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
|
|
G |
Bbln |
bublin coiled coil protein |
decreases expression |
ISO |
Bortezomib results in decreased expression of BBLN mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:15,674,577...15,677,322
Ensembl chr 3:15,674,580...15,677,374
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression increases cleavage increases expression |
ISO |
[arsenic trioxide co-treated with Bortezomib] results in decreased expression of BCL2 mRNA; [Bortezomib co-treated with arsenic trioxide] affects the expression of BCL2 protein; [Bortezomib co-treated with arsenic trioxide] results in decreased expression of BCL2 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of BCL2 protein; [Bortezomib co-treated with Daunorubicin] results in decreased expression of BCL2 mRNA; [Bortezomib co-treated with vorinostat] results in increased cleavage of BCL2 protein; [geldanamycin co-treated with Bortezomib] results in decreased expression of BCL2 protein; [vorinostat co-treated with Bortezomib] results in decreased expression of BCL2 protein; BCL2 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; lonafarnib promotes the reaction [Bortezomib results in increased cleavage of BCL2 protein modified form] Bortezomib results in decreased expression of BCL2 mRNA; Bortezomib results in decreased expression of BCL2 protein Bortezomib results in increased expression of BCL2 mRNA; Bortezomib results in increased expression of BCL2 protein |
CTD |
PMID:15173093 PMID:15781649 PMID:16022909 PMID:16118318 PMID:16446371 PMID:17156654 PMID:17326159 PMID:17327374 PMID:17351739 PMID:17895889 PMID:18718063 PMID:18928586 PMID:20051518 PMID:20383943 PMID:20471514 PMID:21302442 PMID:24377552 More...
|
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2a1 |
BCL2-related protein A1 |
multiple interactions increases expression |
ISO |
[romidepsin co-treated with Bortezomib] results in decreased expression of BCL2A1 protein Bortezomib results in increased expression of BCL2A1A protein |
CTD |
PMID:18223231 PMID:20051518 |
|
NCBI chr 8:89,716,914...89,724,998
Ensembl chr 8:89,716,914...89,724,998
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions decreases response to substance increases cleavage increases expression decreases expression |
ISO |
[alvocidib co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [geldanamycin co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [romidepsin co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [Vorinostat co-treated with Bortezomib] results in decreased expression of BCL2L1 protein alternative form; [Vorinostat co-treated with Bortezomib] results in increased expression of BCL2L1 mRNA alternative form; [Vorinostat co-treated with Bortezomib] results in increased expression of BCL2L1 protein alternative form; BCL2L1 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; BCL2L1 protein results in decreased susceptibility to [Bortezomib co-treated with trichostatin A]; Bortezomib promotes the reaction [capillarisin results in decreased expression of BCL2L1 protein]; lonafarnib promotes the reaction [Bortezomib results in increased cleavage of BCL2L1 protein]; SCIO-469 promotes the reaction [Bortezomib results in decreased expression of BCL2L1 protein]; trichostatin A promotes the reaction [Bortezomib results in decreased expression of BCL2L1 mRNA]; trichostatin A promotes the reaction [Bortezomib results in decreased expression of BCL2L1 protein] BCL2L1 protein results in decreased susceptibility to Bortezomib Bortezomib results in increased expression of BCL2L1 protein Bortezomib results in decreased expression of BCL2L1 mRNA; Bortezomib results in decreased expression of BCL2L1 protein |
CTD |
PMID:15039284 PMID:15543232 PMID:15781649 PMID:16118318 PMID:16446371 PMID:16617327 PMID:16904634 PMID:17326159 PMID:17327374 PMID:17351739 PMID:18223231 PMID:19100720 PMID:20051518 PMID:24333736 More...
|
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 Ensembl chr 1:141,253,523...141,303,479
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
multiple interactions increases response to substance increases activity increases expression |
ISO |
[Bortezomib co-treated with romidepsin] results in increased expression of BCL2L11 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with romidepsin] results in increased expression of BCL2L11 protein]; Bortezomib inhibits the reaction [Arsenic Trioxide results in increased degradation of BCL2L11 protein] BCL2L11 results in increased susceptibility to Bortezomib Bortezomib results in increased activity of BCL2L11 protein Bortezomib results in increased expression of BCL2L11 protein |
CTD |
PMID:15173094 PMID:16024631 PMID:16446371 PMID:17326159 PMID:18566236 PMID:36509116 More...
|
|
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Bcl2l2 |
Bcl2-like 2 |
increases expression |
ISO |
Bortezomib results in increased expression of BCL2L2 mRNA |
CTD |
PMID:18928586 |
|
NCBI chr15:28,346,449...28,361,627
Ensembl chr15:28,356,807...28,361,624
|
|
G |
Bcl3 |
BCL3, transcription coactivator |
multiple interactions decreases expression |
ISO |
[arsenic trioxide co-treated with Bortezomib] results in decreased expression of BCL3 mRNA Bortezomib results in decreased expression of BCL3 mRNA |
CTD |
PMID:20471514 PMID:20977926 |
|
NCBI chr 1:79,471,368...79,485,908
Ensembl chr 1:79,471,369...79,485,607
|
|
G |
Bcl6 |
BCL6, transcription repressor |
increases expression |
ISO |
Bortezomib results in increased expression of BCL6 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr11:76,854,090...76,877,389
Ensembl chr11:76,854,090...76,877,389
|
|
G |
Bcl7a |
BAF chromatin remodeling complex subunit BCL7A |
decreases expression |
ISO |
Bortezomib results in decreased expression of BCL7A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr12:33,211,978...33,243,903
Ensembl chr12:33,223,931...33,243,886
|
|
G |
Bcr |
BCR activator of RhoGEF and GTPase |
decreases expression |
ISO |
Bortezomib results in decreased expression of BCR mRNA |
CTD |
PMID:20977926 |
|
NCBI chr20:13,469,325...13,596,942
Ensembl chr20:13,471,668...13,597,016
|
|
G |
Becn1 |
beclin 1 |
multiple interactions decreases response to substance |
ISO |
BECN1 mutant form promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein] BECN1 protein results in decreased susceptibility to Bortezomib |
CTD |
PMID:22842577 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Bid |
BH3 interacting domain death agonist |
increases cleavage multiple interactions |
ISO |
Bortezomib results in increased cleavage of BID protein [Bortezomib co-treated with Butyrates] results in decreased expression of BID protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of BID protein; [Bortezomib co-treated with vorinostat] results in decreased expression of BID protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of BID protein; [TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of BID protein; [vorinostat co-treated with Bortezomib] results in increased cleavage of BID protein; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of BID protein] |
CTD |
PMID:12893773 PMID:12902978 PMID:15930312 PMID:17326159 PMID:17351739 PMID:17898295 PMID:19261616 More...
|
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Bik |
BCL2-interacting killer |
increases response to substance increases activity increases expression |
ISO |
BIK results in increased susceptibility to Bortezomib Bortezomib results in increased activity of BIK protein Bortezomib results in increased expression of BIK protein |
CTD |
PMID:16446371 PMID:18566236 |
|
NCBI chr 7:114,672,277...114,691,296
Ensembl chr 7:114,672,277...114,691,296
|
|
G |
Bin1 |
bridging integrator 1 |
increases expression |
ISO |
Bortezomib results in increased expression of BIN1 mRNA |
CTD |
PMID:17659339 |
|
NCBI chr18:24,009,731...24,067,267
Ensembl chr18:24,009,653...24,067,263
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
decreases expression multiple interactions |
ISO |
Bortezomib results in decreased expression of BIRC2 protein [geldanamycin co-treated with Bortezomib] results in decreased expression of BIRC2 protein; [romidepsin co-treated with Bortezomib] results in decreased expression of BIRC2 protein |
CTD |
PMID:15543232 PMID:15781649 PMID:17626072 PMID:18223231 |
|
NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
decreases expression multiple interactions increases expression |
ISO |
Bortezomib results in decreased expression of BIRC3 protein [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of BIRC3 mRNA Bortezomib results in increased expression of BIRC3 mRNA; Bortezomib results in increased expression of BIRC3 protein |
CTD |
PMID:17626072 PMID:24085292 PMID:25522274 |
|
NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases expression increases expression multiple interactions |
ISO |
Bortezomib results in decreased expression of BIRC5 mRNA; Bortezomib results in decreased expression of BIRC5 protein Bortezomib results in increased expression of BIRC5 protein [Irinotecan co-treated with Bortezomib] results in decreased expression of BIRC5 protein; [romidepsin co-treated with Bortezomib] results in increased cleavage of BIRC5 protein; Bortezomib promotes the reaction [capillarisin results in decreased expression of BIRC5 protein] |
CTD |
PMID:16373703 PMID:17510429 PMID:17898295 PMID:18223231 PMID:18850583 PMID:19636294 PMID:20977926 PMID:24333736 More...
|
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Birc7 |
baculoviral IAP repeat-containing 7 |
multiple interactions decreases expression |
ISO |
arsenic trioxide promotes the reaction [Bortezomib results in decreased expression of BIRC7 mRNA] |
CTD |
PMID:21867610 |
|
NCBI chr 3:168,047,824...168,052,606
Ensembl chr 3:168,047,824...168,052,606
|
|
G |
Bles03 |
basophilic leukemia expressed protein BLES03 |
decreases expression |
ISO |
Bortezomib results in decreased expression of C11ORF68 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:202,734,555...202,736,809
Ensembl chr 1:202,734,555...202,736,804
|
|
G |
Blk |
BLK proto-oncogene, Src family tyrosine kinase |
decreases expression |
ISO |
Bortezomib results in decreased expression of BLK mRNA |
CTD |
PMID:20977926 |
|
NCBI chr15:37,626,746...37,665,053
Ensembl chr15:37,627,039...37,665,031
|
|
G |
Blvrb |
biliverdin reductase B |
increases expression |
ISO |
Bortezomib results in increased expression of BLVRB mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:82,738,646...82,756,312
Ensembl chr 1:82,738,695...82,770,375
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
increases expression |
ISO |
Bortezomib results in increased expression of BNIP3 protein |
CTD |
PMID:20110775 |
|
NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359
|
|
G |
Brca1 |
BRCA1, DNA repair associated |
decreases expression increases response to substance decreases ubiquitination multiple interactions |
ISO |
Bortezomib results in decreased expression of BRCA1 mRNA BRCA1 mutant form results in increased susceptibility to Bortezomib Bortezomib results in decreased ubiquitination of BRCA1 protein [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of AKR7A2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNF mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNG2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CRYGEP mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DAPK2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DLGAP5 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of EGLN3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of FZD2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of H3C6 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of LGR4 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of RPS7P5 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of THRA mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of TNFAIP8L1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of TNKS mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased activity of E2F1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ARID3B mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ATF3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of BIRC3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CCNB1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CRYAB mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CTH mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of DUSP5 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ERN1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of FGF21 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GADD45A mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GDF15 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of HECW1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of HIKESHI mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of IL7R mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of KRTAP21-1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of MIR568 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of PAWR mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of PCYT1A mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of RND3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TNFAIP3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TNFRSF9 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TRIB3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TRIML2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ZNF613 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased phosphorylation of RB1 protein; TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein]; TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased phosphorylation of RB1 protein] BRCA1 gene mutant form results in increased susceptibility to Bortezomib BRCA1 protein inhibits the reaction [BRCA1 gene mutant form results in increased susceptibility to Bortezomib] |
CTD |
PMID:21917757 PMID:25522274 |
|
NCBI chr10:86,417,441...86,477,762
Ensembl chr10:86,418,000...86,477,304
|
|
G |
Brca2 |
BRCA2, DNA repair associated |
decreases expression multiple interactions |
ISO |
Bortezomib results in decreased expression of BRCA2 mRNA [arsenic trioxide co-treated with Bortezomib] results in increased expression of BRCA2 mRNA |
CTD |
PMID:21917757 PMID:25913414 |
|
NCBI chr12:59,492...103,789
Ensembl chr12:59,819...100,567
|
|
G |
Brcc3 |
BRCA1/BRCA2-containing complex subunit 3 |
decreases expression |
ISO |
Bortezomib results in decreased expression of BRCC3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 9:1,986,942...1,989,484
Ensembl chr 9:1,986,575...1,991,080
|
|
G |
Brf2 |
BRF2 general transcription factor 3B subunit |
increases expression |
ISO |
Bortezomib results in increased expression of BRF2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr16:64,928,334...64,933,057
Ensembl chr16:64,928,300...64,933,059
|
|
G |
Bsdc1 |
BSD domain containing 1 |
increases expression |
ISO |
Bortezomib results in increased expression of BSDC1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:141,798,918...141,827,091
Ensembl chr 5:141,798,981...141,827,092
|
|
G |
C17h6orf62 |
similar to human chromosome 6 open reading frame 62 |
increases expression |
ISO |
Bortezomib results in increased expression of C6ORF62 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:40,256,211...40,267,851
Ensembl chr17:40,256,211...40,276,020
|
|
G |
C1h9orf85 |
similar to human chromosome 9 open reading frame 85 |
increases expression |
ISO |
Bortezomib results in increased expression of C9ORF85 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:219,136,085...219,197,723
Ensembl chr 1:219,138,201...219,198,435
|
|
G |
C6h14orf132 |
similar to human chromosome 14 open reading frame 132 |
decreases expression |
ISO |
Bortezomib results in decreased expression of C14ORF132 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:124,365,466...124,398,449
|
|
G |
Caap1 |
caspase activity and apoptosis inhibitor 1 |
increases expression |
ISO |
Bortezomib results in increased expression of CAAP1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:109,313,253...109,414,323
Ensembl chr 5:109,361,912...109,414,314
|
|
G |
Cacna1h |
calcium voltage-gated channel subunit alpha1 H |
decreases degradation |
ISO |
Bortezomib results in decreased degradation of CACNA1H protein |
CTD |
PMID:30552955 |
|
NCBI chr10:14,390,104...14,448,204
Ensembl chr10:14,390,113...14,448,376
|
|
G |
Calr |
calreticulin |
multiple interactions increases expression |
ISO |
[CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CALR mRNA]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; [Chloroquine co-treated with Bortezomib] promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; [Chloroquine co-treated with Bortezomib] results in increased expression of and affects the localization of CALR protein; [Chloroquine co-treated with Bortezomib] results in increased expression of CALR mRNA; Bortezomib promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; Bortezomib results in increased expression of and affects the localization of CALR protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR mRNA]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] affects the localization of CALR protein]; DDIT3 protein affects the reaction [Bortezomib affects the localization of CALR protein]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] affects the localization of CALR protein]; Doxorubicin promotes the reaction [Bortezomib affects the localization of CALR protein] [Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]] |
CTD |
PMID:30482226 |
|
NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
|
|
G |
Capn15 |
calpain 15 |
decreases expression |
ISO |
Bortezomib results in decreased expression of CAPN15 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:14,972,807...14,999,411
Ensembl chr10:14,972,800...14,999,508
|
|
G |
Car9 |
carbonic anhydrase 9 |
decreases expression |
ISO |
Bortezomib results in decreased expression of CA9 protein |
CTD |
PMID:16061869 |
|
NCBI chr 5:57,763,234...57,769,838
Ensembl chr 5:57,763,206...57,769,838
|
|
G |
Card9 |
caspase recruitment domain family, member 9 |
multiple interactions |
ISO |
[arsenic trioxide co-treated with Bortezomib] results in increased expression of CARD9 mRNA |
CTD |
PMID:20471514 |
|
NCBI chr 3:9,171,814...9,180,310
Ensembl chr 3:9,171,815...9,180,237
|
|
G |
Casp12 |
caspase 12 |
increases cleavage |
ISO |
Bortezomib results in increased cleavage of CASP12 protein |
CTD |
PMID:15509775 PMID:16357177 |
|
NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037
|
|
G |
Casp2 |
caspase 2 |
multiple interactions increases cleavage increases response to substance |
ISO |
benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP2 protein]; Bortezomib promotes the reaction [Brefeldin A results in increased cleavage of and results in increased activity of CASP2 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP2 protein; Brefeldin A promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP2 protein]; CASP2 protein affects the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein] Bortezomib results in increased cleavage of CASP2 protein CASP2 results in increased susceptibility to Bortezomib |
CTD |
PMID:15509775 PMID:16446371 PMID:18723477 |
|
NCBI chr 4:71,149,632...71,167,388
Ensembl chr 4:71,149,669...71,167,379
|
|
G |
Casp3 |
caspase 3 |
increases activity increases cleavage increases expression multiple interactions |
ISO |
Bortezomib results in increased activity of CASP3 protein Bortezomib results in increased cleavage of CASP3 protein Bortezomib results in increased expression of CASP3 protein 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt affects the reaction [Bortezomib results in increased cleavage of CASP3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein]; [Arsenic Trioxide co-treated with Bortezomib] results in increased activity of CASP3 protein; [Arsenic Trioxide co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in increased activity of CASP3 protein; [Bortezomib co-treated with abexinostat] results in increased activity of CASP3 protein; [Bortezomib co-treated with Arsenic Trioxide] affects the expression of CASP3 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased activity of CASP3 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased expression of CASP3 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with Doxorubicin] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with N,N-dimethylsphingosine] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib co-treated with oblimersen co-treated with Cyclophosphamide] results in increased activity of CASP3 protein; [Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib co-treated with Vorinostat] results in increased activity of CASP3 protein; [Bortezomib co-treated with Vorinostat] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP3 protein; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of ATM protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of MDM2 protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of PRKDC protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased phosphorylation of TP53 protein]; [Cisplatin co-treated with Bortezomib] results in increased activity of CASP3 protein; [Dexamethasone co-treated with Bortezomib] results in increased activity of CASP3 protein; [gambogic acid co-treated with Bortezomib] results in increased activity of CASP3 protein; [lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [nutlin 3 co-treated with Bortezomib] results in increased activity of CASP3 protein; [TNFSF10 protein co-treated with Bortezomib] results in increased activity of CASP3 protein; [trichostatin A co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [Vorinostat co-treated with Bortezomib] results in increased activity of CASP3 protein; [Vorinostat co-treated with Bortezomib] results in increased cleavage of CASP3 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP3 protein]; BECN1 mutant form promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[gambogic acid co-treated with Bortezomib] results in increased activity of CASP3 protein]; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Betulinic Acid inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [belinostat results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [Butyrates results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [capillarisin results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [gallium nitrate results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [NSC606985 results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [romidepsin results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [Thapsigargin results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [Tunicamycin results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [Vorinostat results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP3 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; DDIT3 protein affects the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; MAPK14 mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; PMAIP1 protein promotes the reaction [[Bortezomib co-treated with Arsenic Trioxide] results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; ricolinostat promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; STK4 mutant form inhibits the reaction [Bortezomib results in increased activity of CASP3 protein]; TNFRSF10B mutant form inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein]; TNFRSF10B mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased activity of CASP3 protein]; ZFAND2A protein inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein] 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein]; [Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein; [Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [SCIO-469 co-treated with Bortezomib] results in increased activity of CASP3 protein; ATG5 gene mutant form inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; ATG5 gene mutant form inhibits the reaction [HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]]; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Betulinic Acid inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]]; HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein] |
CTD |
PMID:12393500 PMID:12893773 PMID:15070698 PMID:15173093 PMID:15509775 PMID:15514602 PMID:15930312 PMID:16024631 PMID:16118318 PMID:16357177 PMID:16617327 PMID:16675587 PMID:16778179 PMID:16904634 PMID:16985072 PMID:17121930 PMID:17156654 PMID:17326159 PMID:17351739 PMID:17495969 PMID:17510429 PMID:17898295 PMID:17898787 PMID:18005386 PMID:18223231 PMID:18223318 PMID:18342500 PMID:18534018 PMID:18641367 PMID:18718063 PMID:18790767 PMID:19100720 PMID:19261616 PMID:19417023 PMID:19662097 PMID:20022965 PMID:20051518 PMID:20150630 PMID:20383943 PMID:20471514 PMID:20524303 PMID:20850924 PMID:21195056 PMID:21345073 PMID:21472287 PMID:21518486 PMID:22262760 PMID:22842577 PMID:23063726 PMID:23300809 PMID:24291039 PMID:24333736 PMID:24377552 PMID:29384525 PMID:30482226 PMID:31540997 PMID:33775688 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp4 |
caspase 4 |
multiple interactions increases activity increases cleavage increases response to substance |
ISO |
[Bortezomib co-treated with vorinostat] results in increased activity of CASP4 protein; CASP4 protein results in increased susceptibility to [Cisplatin co-treated with Bortezomib]; PMAIP1 protein promotes the reaction [[Bortezomib co-treated with vorinostat] results in increased activity of CASP4 protein]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased cleavage of CASP4 protein] Bortezomib results in increased activity of CASP4 protein CASP4 protein results in increased susceptibility to Bortezomib |
CTD |
PMID:16357177 PMID:18641367 |
|
NCBI chr 8:2,599,017...2,635,097
Ensembl chr 8:2,598,876...2,635,092
|
|
G |
Casp6 |
caspase 6 |
multiple interactions increases cleavage |
ISO |
Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of CASP6 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP6 protein] |
CTD |
PMID:16617327 PMID:17510429 |
|
NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502
|
|
G |
Casp7 |
caspase 7 |
multiple interactions increases activity increases cleavage |
ISO |
[Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP7 protein; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP7 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP7 protein; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP7 protein]; ZFAND2A protein affects the reaction [Bortezomib results in increased cleavage of CASP7 protein] Bortezomib results in increased activity of CASP7 protein |
CTD |
PMID:16024631 PMID:16617327 PMID:16904634 PMID:18342500 PMID:18534018 PMID:20022965 PMID:20524303 PMID:23300809 PMID:31540997 More...
|
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases cleavage |
ISO |
[Arsenic Trioxide co-treated with Bortezomib] results in decreased expression of CASP8 mRNA; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in increased activity of CASP8 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased expression of CASP8 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of and results in increased activity of CASP8 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP8 protein; [Bortezomib co-treated with Vorinostat] results in increased activity of CASP8 protein; [Bortezomib co-treated with Vorinostat] results in increased cleavage of and results in increased activity of CASP8 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP8 protein; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of ATM protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of MDM2 protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of PRKDC protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased phosphorylation of TP53 protein]; [gambogic acid co-treated with Bortezomib] results in increased activity of CASP8 protein; [IFNA2 protein co-treated with Bortezomib] results in increased activity of CASP8 protein; [lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP8 protein; [TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of CASP8 protein; [trichostatin A co-treated with Bortezomib] results in increased cleavage of CASP8 protein; [Vorinostat co-treated with Bortezomib] results in increased cleavage of CASP8 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [abexinostat results in increased cleavage of CASP8 protein]; Bortezomib promotes the reaction [Arsenic Trioxide results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [Butyrates results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of CASP8 protein]; Bortezomib promotes the reaction [Vorinostat results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP8 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP8 protein; CDKN1A protein affects the reaction [[TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of CASP8 protein]; ricolinostat promotes the reaction [Bortezomib results in increased cleavage of CASP8 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP8 protein]; TNFRSF10B mutant form inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein]; TNFRSF10B mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP8 protein]; ZFAND2A protein affects the reaction [Bortezomib results in increased cleavage of CASP8 protein] |
CTD |
PMID:12393500 PMID:12893773 PMID:12902978 PMID:15070698 PMID:15173093 PMID:15930312 PMID:16024631 PMID:16118318 PMID:16617327 PMID:16778179 PMID:16904634 PMID:17172406 PMID:17326159 PMID:17351739 PMID:17510429 PMID:17620439 PMID:17626072 PMID:17659339 PMID:17898787 PMID:18005386 PMID:18641367 PMID:19100720 PMID:19261616 PMID:19417023 PMID:20051518 PMID:20442297 PMID:20471514 PMID:21345073 PMID:22262760 PMID:24291039 PMID:24377552 PMID:31540997 More...
|
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases cleavage increases response to substance increases expression |
ISO |
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt affects the reaction [Bortezomib results in increased cleavage of CASP9 protein]; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in increased activity of CASP9 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased activity of CASP9 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased expression of CASP9 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of and results in increased activity of CASP9 protein; [Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP9 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP9 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP9 protein; [Bortezomib co-treated with Vorinostat] results in increased activity of CASP9 protein; [Bortezomib co-treated with Vorinostat] results in increased cleavage of and results in increased activity of CASP9 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP9 protein; [gambogic acid co-treated with Bortezomib] results in increased activity of CASP9 protein; [lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP9 protein; [nutlin 3 co-treated with Bortezomib] results in increased activity of CASP9 protein; [ricolinostat co-treated with Bortezomib] results in increased cleavage of CASP9 protein; [trichostatin A co-treated with Bortezomib] results in increased cleavage of CASP9 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP9 protein]; benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]; benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[gambogic acid co-treated with Bortezomib] results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [abexinostat results in increased cleavage of CASP9 protein]; Bortezomib promotes the reaction [Arsenic Trioxide results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [belinostat results in increased cleavage of CASP9 protein]; Bortezomib promotes the reaction [Butyrates results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [romidepsin results in increased cleavage of CASP9 protein]; Bortezomib promotes the reaction [Vorinostat results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP9 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein; CASP2 protein affects the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP9 protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased cleavage of CASP9 protein]; ZFAND2A protein affects the reaction [Bortezomib results in increased cleavage of CASP9 protein] CASP9 gene SNP results in increased susceptibility to Bortezomib; CASP9 results in increased susceptibility to Bortezomib Bortezomib results in increased expression of CASP9 protein |
CTD |
PMID:12893773 PMID:15070698 PMID:15173093 PMID:15509775 PMID:16024631 PMID:16118318 PMID:16617327 PMID:16778179 PMID:16904634 PMID:16985072 PMID:17156654 PMID:17326159 PMID:17510429 PMID:17620439 PMID:17626072 PMID:17898295 PMID:17898787 PMID:18005386 PMID:18223231 PMID:18641367 PMID:18723477 PMID:19261616 PMID:19417023 PMID:20051518 PMID:20471514 PMID:20850924 PMID:20864405 PMID:21345073 PMID:21518486 PMID:22262760 PMID:24291039 PMID:24377552 PMID:31540997 More...
|
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
decreases expression multiple interactions |
EXP |
Bortezomib results in decreased expression of CAT protein Berberine inhibits the reaction [Bortezomib results in decreased expression of CAT protein] |
CTD |
PMID:35121005 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cbl |
Cbl proto-oncogene |
multiple interactions |
ISO |
[Bortezomib results in decreased activity of CBL protein] promotes the reaction [arsenic trioxide results in increased activity of AKT1 protein] |
CTD |
PMID:19457607 |
|
NCBI chr 8:44,487,824...44,571,620
Ensembl chr 8:44,489,410...44,571,176
|
|
G |
Cbr3 |
carbonyl reductase 3 |
increases expression |
ISO |
[Bortezomib results in increased expression of NFE2L2 protein] which results in increased expression of CBR3 mRNA; Bortezomib results in increased expression of CBR3 mRNA |
CTD |
PMID:20806931 PMID:20977926 |
|
NCBI chr11:33,008,615...33,016,877
Ensembl chr11:33,008,615...33,016,875
|
|
G |
Cbx3 |
chromobox 3 |
increases expression |
ISO |
Bortezomib results in increased expression of CBX3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:80,545,450...80,559,284
Ensembl chr 4:80,546,010...80,559,283 Ensembl chr 4:80,546,010...80,559,283
|
|
G |
Ccar1 |
cell division cycle and apoptosis regulator 1 |
increases expression |
ISO |
Bortezomib results in increased expression of CCAR1 protein |
CTD |
PMID:21594647 PMID:21903591 |
|
NCBI chr20:30,685,916...30,728,531
Ensembl chr20:30,685,916...30,728,526
|
|
G |
Ccdc186 |
coiled-coil domain containing 186 |
increases expression |
ISO |
Bortezomib results in increased expression of CCDC186 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:255,831,663...255,871,954
Ensembl chr 1:255,839,595...255,871,935
|
|
G |
Ccdc32 |
coiled-coil domain containing 32 |
increases expression |
ISO |
Bortezomib results in increased expression of CCDC32 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:105,998,429...106,010,985
Ensembl chr 3:105,998,430...106,010,975
|
|
G |
Ccdc6 |
coiled-coil domain containing 6 |
decreases expression |
ISO |
Bortezomib results in decreased expression of CCDC6 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr20:18,432,177...18,528,186
Ensembl chr20:18,433,695...18,528,658
|
|
G |
Ccdc82 |
coiled-coil domain containing 82 |
increases expression |
ISO |
Bortezomib results in increased expression of CCDC82 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 8:10,227,727...10,265,963
Ensembl chr 8:10,228,430...10,265,963
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of CCL2 mRNA |
CTD |
PMID:20471514 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
increases expression decreases expression |
EXP ISO |
Bortezomib results in increased expression of CCL3 mRNA; Bortezomib results in increased expression of CCL3 protein Bortezomib results in decreased expression of CCL3 mRNA |
CTD |
PMID:18089816 PMID:20830808 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccnb1 |
cyclin B1 |
multiple interactions increases expression |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CCNB1 protein; Bortezomib results in increased ubiquitination of and results in increased expression of CCNB1 protein Bortezomib results in increased expression of CCNB1 protein |
CTD |
PMID:19074855 PMID:20367638 PMID:25522274 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
[[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of CCND1 protein; [[Bortezomib co-treated with Vorinostat] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of CCND1 protein; [Bortezomib co-treated with Butyrates] results in decreased expression of CCND1 protein; [Bortezomib co-treated with Vorinostat] results in decreased expression of CCND1 protein; [geldanamycin co-treated with Bortezomib] results in decreased expression of CCND1 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of CCND1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of CCND1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Vorinostat] results in decreased expression of CCND1 protein]; Bortezomib promotes the reaction [capillarisin results in decreased expression of CCND1 protein] |
CTD |
PMID:12893773 PMID:15173093 PMID:15781649 PMID:24333736 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd2 |
cyclin D2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of CCND2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Ccnf |
cyclin F |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNF mRNA |
CTD |
PMID:25522274 |
|
NCBI chr10:13,253,073...13,279,140
Ensembl chr10:13,253,380...13,279,101
|
|
G |
Ccng2 |
cyclin G2 |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNG2 mRNA |
CTD |
PMID:25522274 |
|
NCBI chr14:14,804,321...14,812,819
Ensembl chr14:14,804,322...14,812,830
|
|
G |
Ccpg1 |
cell cycle progression 1 |
increases expression |
ISO |
Bortezomib results in increased expression of CCPG1 mRNA |
CTD |
PMID:20471514 PMID:20977926 |
|
NCBI chr 8:73,719,960...73,752,437
Ensembl chr 8:73,719,955...73,752,430
|
|
G |
Cd27 |
CD27 molecule |
increases expression |
ISO |
Bortezomib results in increased expression of CD27 mRNA |
CTD |
PMID:17895889 |
|
NCBI chr 4:158,030,700...158,035,862
Ensembl chr 4:158,030,703...158,035,592
|
|
G |
Cd38 |
CD38 molecule |
decreases expression |
ISO |
Bortezomib results in decreased expression of CD38 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr14:67,172,062...67,212,328
Ensembl chr14:67,172,063...67,211,986
|
|
G |
Cd5 |
Cd5 molecule |
decreases expression |
ISO |
Bortezomib results in decreased expression of CD5 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:207,365,337...207,386,313
Ensembl chr 1:207,365,337...207,386,313
|
|
G |
Cd69 |
Cd69 molecule |
increases expression |
ISO |
Bortezomib results in increased expression of CD69 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:162,725,446...162,733,364
Ensembl chr 4:162,725,446...162,733,542
|
|
G |
Cd79a |
CD79a molecule |
decreases expression |
ISO |
Bortezomib results in decreased expression of CD79A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:80,493,581...80,497,936
Ensembl chr 1:80,493,581...80,497,935
|
|
G |
Cd82 |
Cd82 molecule |
decreases expression |
ISO |
Bortezomib results in decreased expression of CD82 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:79,387,361...79,431,847
Ensembl chr 3:79,385,887...79,431,809
|
|
G |
Cd9 |
CD9 molecule |
increases expression |
ISO |
Bortezomib results in increased expression of CD9 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:158,256,328...158,289,136
Ensembl chr 4:158,256,328...158,289,222
|
|
G |
Cdc23 |
cell division cycle 23 |
increases expression |
ISO |
Bortezomib results in increased expression of CDC23 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr18:26,236,891...26,260,611
Ensembl chr18:26,236,890...26,291,163
|
|
G |
Cdc34 |
cell division cycle 34, ubiqiutin conjugating enzyme |
increases expression |
ISO |
Bortezomib results in increased expression of CDC34 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:10,017,588...10,023,586
Ensembl chr 7:10,017,588...10,023,186
|
|
G |
Cdc37 |
cell division cycle 37, HSP90 cochaperone |
increases expression |
ISO |
Bortezomib results in increased expression of CDC37 mRNA |
CTD |
PMID:17895889 |
|
NCBI chr 8:19,677,400...19,690,761
Ensembl chr 8:19,671,938...19,690,809
|
|
G |
Cdc42 |
cell division cycle 42 |
decreases expression |
ISO |
Bortezomib results in decreased expression of CDC42 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:149,555,069...149,593,239
Ensembl chr 5:149,553,724...149,593,111
|
|
G |
Cdc42se2 |
CDC42 small effector 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of CDC42SE2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:38,836,549...38,905,056
Ensembl chr10:38,836,555...38,905,059 Ensembl chr 1:38,836,555...38,905,059
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
multiple interactions decreases activity increases activity increases phosphorylation |
ISO |
Bortezomib inhibits the reaction [docetaxel results in increased activity of CDK1 protein] Bortezomib results in decreased activity of CDK1 protein Bortezomib results in increased activity of CDK1 protein Bortezomib results in increased phosphorylation of CDK1 protein |
CTD |
PMID:14749476 PMID:16928825 PMID:19074855 PMID:20367638 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions decreases activity |
ISO |
Bortezomib inhibits the reaction [docetaxel results in increased activity of CDK2 protein] Bortezomib results in decreased activity of CDK2 protein |
CTD |
PMID:14749476 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases stability increases expression decreases response to substance multiple interactions |
ISO |
Bortezomib results in increased stability of CDKN1A protein Bortezomib results in increased expression of CDKN1A mRNA; Bortezomib results in increased expression of CDKN1A protein CDKN1A results in decreased susceptibility to Bortezomib [Bortezomib co-treated with Butyrates] results in increased cleavage of CDKN1A protein; [Bortezomib co-treated with Butyrates] results in increased expression of and results in increased cleavage of CDKN1A protein; [Bortezomib co-treated with vorinostat] results in increased cleavage of CDKN1A protein; [Bortezomib co-treated with vorinostat] results in increased expression of and results in increased cleavage of CDKN1A protein; [TNFSF10 protein co-treated with Bortezomib] results in increased expression of CDKN1A protein; [trichostatin A co-treated with Bortezomib] results in increased expression of CDKN1A mRNA; [trichostatin A co-treated with Bortezomib] results in increased expression of CDKN1A protein; [vorinostat co-treated with Bortezomib] results in increased expression of CDKN1A protein; Bortezomib promotes the reaction [abexinostat results in increased expression of CDKN1A protein]; CDKN1A protein affects the reaction [[TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of CASP8 protein]; CDKN1A results in decreased susceptibility to [Bortezomib co-treated with docetaxel] |
CTD |
PMID:12893773 PMID:12902978 PMID:14749476 PMID:15173093 PMID:15543232 PMID:15930312 PMID:16928825 PMID:17327374 PMID:17898295 PMID:18223318 PMID:18445700 PMID:18790767 PMID:19220424 PMID:19417023 PMID:20383943 PMID:20977926 PMID:21345073 PMID:36401358 More...
|
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions increases expression increases stability |
ISO |
[Bortezomib co-treated with Butyrates] results in increased cleavage of CDKN1B protein; [Bortezomib co-treated with Vorinostat] results in increased cleavage of CDKN1B protein; [Vorinostat co-treated with Bortezomib] results in increased expression of CDKN1B protein; Bortezomib promotes the reaction [Lapatinib results in increased expression of CDKN1B protein]; Cisplatin promotes the reaction [Bortezomib results in increased expression of CDKN1B protein]; Lapatinib promotes the reaction [Bortezomib results in increased expression of CDKN1B protein] Bortezomib results in increased stability of CDKN1B protein |
CTD |
PMID:14749476 PMID:15173093 PMID:15543232 PMID:18223318 PMID:18445700 PMID:18850583 PMID:19220424 PMID:19636294 PMID:20701607 More...
|
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdt1 |
chromatin licensing and DNA replication factor 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of CDT1 mRNA |
CTD |
PMID:17659339 |
|
NCBI chr19:50,620,713...50,625,659
Ensembl chr19:50,620,713...50,625,659
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions |
ISO |
Bortezomib inhibits the reaction [NSC606985 results in decreased expression of CEBPA protein] |
CTD |
PMID:19662097 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
multiple interactions decreases expression increases expression |
ISO EXP |
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CEBPB protein alternative form]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CEBPB protein alternative form]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CALR mRNA]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; [Chloroquine co-treated with Bortezomib] promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; [Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of CEBPB protein alternative form]; Bortezomib inhibits the reaction [Arsenic Trioxide results in decreased expression of CEBPB mRNA]; Bortezomib promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR mRNA]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of CEBPB protein alternative form] Bortezomib results in decreased expression of CEBPB mRNA 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CEBPB protein alternative form]; [Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of CEBPB protein alternative form]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of CEBPB protein alternative form]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]] |
CTD |
PMID:20471514 PMID:20830808 PMID:30482226 |
|
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Cenpc |
centromere protein C |
increases expression |
ISO |
Bortezomib results in increased expression of CENPC mRNA |
CTD |
PMID:20977926 |
|
NCBI chr14:21,988,067...22,046,732
Ensembl chr14:21,988,144...22,055,476
|
|
G |
Cep290 |
centrosomal protein 290 |
increases expression |
ISO |
Bortezomib results in increased expression of CEP290 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:35,310,071...35,399,388
Ensembl chr 7:35,310,199...35,399,392
|
|
G |
Cers2 |
ceramide synthase 2 |
multiple interactions |
ISO |
Bortezomib inhibits the reaction [CERS2 protein affects the expression of ABCB1 protein] |
CTD |
PMID:34915026 |
|
NCBI chr 2:182,890,527...182,898,805
Ensembl chr 2:182,890,493...182,933,314
|
|
G |
Cers6 |
ceramide synthase 6 |
multiple interactions |
ISO |
Bortezomib inhibits the reaction [CERS6 protein affects the expression of ABCB1 protein] |
CTD |
PMID:34915026 |
|
NCBI chr 3:53,630,637...53,879,692
Ensembl chr 3:53,630,959...53,876,848
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
affects expression increases expression decreases expression decreases response to substance multiple interactions |
ISO |
Bortezomib affects the expression of CFLAR protein Bortezomib results in increased expression of CFLAR protein; Bortezomib results in increased expression of CFLAR protein alternative form; Bortezomib results in increased expression of CFLAR protein modified form Bortezomib results in decreased expression of CFLAR mRNA; Bortezomib results in decreased expression of CFLAR protein CFLAR protein alternative form results in decreased susceptibility to Bortezomib; CFLAR results in decreased susceptibility to Bortezomib [Bortezomib co-treated with TNFSF10 protein] results in decreased expression of CFLAR protein; [romidepsin co-treated with Bortezomib] results in decreased expression of CFLAR protein; TNFSF10 protein promotes the reaction [Bortezomib results in decreased expression of CFLAR protein] |
CTD |
PMID:17326159 PMID:17327374 PMID:17351739 PMID:17510429 PMID:17659339 PMID:18223231 PMID:19100720 PMID:19922463 PMID:20515944 PMID:20876774 More...
|
|
NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
|
|
G |
Cgref1 |
cell growth regulator with EF hand domain 1 |
increases expression |
ISO |
Bortezomib results in increased expression of CGREF1 mRNA |
CTD |
PMID:17895889 |
|
NCBI chr 6:25,431,846...25,443,853
Ensembl chr 6:25,431,799...25,443,852
|
|
G |
Chac1 |
ChaC glutathione-specific gamma-glutamylcyclotransferase 1 |
increases expression |
ISO |
Bortezomib results in increased expression of CHAC1 mRNA |
CTD |
PMID:15509775 |
|
NCBI chr 3:106,342,302...106,345,526
Ensembl chr 3:106,342,302...106,345,526
|
|
G |
Chaf1a |
chromatin assembly factor 1 subunit A |
decreases expression |
ISO |
Bortezomib results in decreased expression of CHAF1A mRNA |
CTD |
PMID:17659339 |
|
NCBI chr 9:873,953...900,701
Ensembl chr 9:874,051...900,654
|
|
G |
Chd2 |
chromodomain helicase DNA binding protein 2 |
increases expression |
ISO |
Bortezomib results in increased expression of CHD2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:127,188,146...127,317,041
Ensembl chr 1:127,190,059...127,300,502
|
|
G |
Chfr |
checkpoint with forkhead and ring finger domains |
decreases expression |
ISO |
Bortezomib results in decreased expression of CHFR mRNA |
CTD |
PMID:20977926 |
|
NCBI chr12:46,504,497...46,538,104
Ensembl chr12:46,504,497...46,538,014
|
|
G |
Chst11 |
carbohydrate sulfotransferase 11 |
decreases expression |
ISO |
Bortezomib results in decreased expression of CHST11 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:20,524,535...20,743,008
Ensembl chr 7:20,528,100...20,743,111
|
|
G |
Chst2 |
carbohydrate sulfotransferase 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of CHST2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 8:95,960,067...95,966,312
Ensembl chr 8:95,959,826...95,966,955
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
increases expression increases activity |
ISO |
Bortezomib results in increased expression of CHUK mRNA Bortezomib results in increased activity of CHUK protein |
CTD |
PMID:20471514 PMID:24085292 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Cideb |
cell death-inducing DFFA-like effector b |
decreases expression |
ISO |
Bortezomib results in decreased expression of CIDEB mRNA |
CTD |
PMID:17659339 |
|
NCBI chr15:29,252,208...29,256,482
Ensembl chr15:29,252,213...29,256,605
|
|
G |
Cilk1 |
ciliogenesis associated kinase 1 |
increases expression |
ISO |
Bortezomib results in increased expression of CILK1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 8:78,984,075...79,042,695
Ensembl chr 8:78,984,258...79,042,691
|
|
G |
Clec7a |
C-type lectin domain containing 7A |
increases expression |
ISO |
Bortezomib results in increased expression of CLEC7A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:162,902,731...162,913,931
Ensembl chr 4:162,902,732...162,913,897
|
|
G |
Clip4 |
CAP-GLY domain containing linker protein family, member 4 |
increases expression |
ISO |
Bortezomib results in increased expression of CLIP4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:23,616,280...23,697,625 NCBI chr 6:23,718,580...23,729,231 NCBI chr 6:23,597,729...23,601,000
Ensembl chr 6:23,616,281...23,677,874
|
|
G |
Cln6 |
CLN6, transmembrane ER protein |
decreases expression |
ISO |
Bortezomib results in decreased expression of CLN6 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 8:63,303,356...63,318,360
Ensembl chr 8:63,303,029...63,318,360
|
|
G |
Clptm1 |
CLPTM1 regulator of GABA type A receptor forward trafficking |
decreases expression |
ISO |
Bortezomib results in decreased expression of CLPTM1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:79,289,478...79,321,079
Ensembl chr 1:79,289,477...79,321,092
|
|
G |
Clu |
clusterin |
increases expression |
ISO |
Bortezomib results in increased expression of CLU mRNA |
CTD |
PMID:20977926 |
|
NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315
|
|
G |
Cox8a |
cytochrome c oxidase subunit 8A |
decreases expression |
ISO |
Bortezomib results in decreased expression of COX8A mRNA |
CTD |
PMID:30818834 |
|
NCBI chr 1:204,402,118...204,404,439
|
|
G |
Cpt1c |
carnitine palmitoyltransferase 1c |
increases response to substance |
ISO |
CPT1C gene SNP results in increased susceptibility to Bortezomib |
CTD |
PMID:20864405 |
|
NCBI chr 1:95,442,814...95,457,347
Ensembl chr 1:95,442,817...95,457,342
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
decreases expression multiple interactions |
EXP |
Bortezomib results in decreased expression of CREB1 protein Berberine inhibits the reaction [Bortezomib results in decreased expression of CREB1 protein] |
CTD |
PMID:35121005 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Crebbp |
CREB binding protein |
decreases expression |
ISO |
Bortezomib results in decreased expression of CREBBP mRNA |
CTD |
PMID:25913414 |
|
NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888
|
|
G |
Crem |
cAMP responsive element modulator |
increases expression |
ISO |
Bortezomib results in increased expression of CREM mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:54,238,889...54,305,989
Ensembl chr17:54,239,030...54,305,989
|
|
G |
Crip2 |
cysteine-rich protein 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of CRIP2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:132,221,120...132,226,066
Ensembl chr 6:132,221,082...132,226,065
|
|
G |
Cripto |
cripto, EGF-CFC family member |
increases expression |
ISO |
Bortezomib results in increased expression of CRIPTO mRNA |
CTD |
PMID:17895889 |
|
NCBI chr 8:110,924,774...110,938,545
Ensembl chr 8:110,925,024...110,930,308
|
|
G |
Crkl |
CRK like proto-oncogene, adaptor protein |
multiple interactions |
ISO |
[alvocidib co-treated with Bortezomib co-treated with ABL1] results in decreased phosphorylation of CRKL protein |
CTD |
PMID:15039284 |
|
NCBI chr11:83,528,788...83,563,214
Ensembl chr11:83,526,530...83,563,238
|
|
G |
Cryab |
crystallin, alpha B |
multiple interactions increases expression |
ISO EXP |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CRYAB mRNA Bortezomib results in increased expression of CRYAB mRNA |
CTD |
PMID:20830808 PMID:25522274 |
|
NCBI chr 8:51,093,441...51,099,161
Ensembl chr 8:51,093,441...51,099,157
|
|
G |
Cst7 |
cystatin F |
increases expression |
ISO |
Bortezomib results in increased expression of CST7 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:139,396,830...139,405,557
Ensembl chr 3:139,396,850...139,405,557
|
|
G |
Ctdspl2 |
CTD small phosphatase like 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of CTDSPL2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:108,915,263...108,970,620
Ensembl chr 3:108,915,280...108,967,227
|
|
G |
Cth |
cystathionine gamma-lyase |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CTH mRNA |
CTD |
PMID:25522274 |
|
NCBI chr 2:246,975,888...247,002,234
Ensembl chr 2:246,975,894...247,002,234
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions increases expression decreases response to substance |
ISO |
2-methoxyestradiol inhibits the reaction [CTNNB1 protein results in decreased susceptibility to Bortezomib]; arsenic trioxide inhibits the reaction [CTNNB1 protein results in decreased susceptibility to Bortezomib]; TNFSF10 protein inhibits the reaction [Bortezomib results in increased expression of CTNNB1 protein] |
CTD |
PMID:18485479 PMID:19100720 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Ctsb |
cathepsin B |
multiple interactions increases localization |
ISO |
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Bortezomib results in increased localization of CTSB protein] |
CTD |
PMID:16446371 |
|
NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500
|
|
G |
Ctsd |
cathepsin D |
increases expression |
ISO |
Bortezomib results in increased expression of CTSD mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Cul1 |
cullin 1 |
increases expression |
ISO |
Bortezomib results in increased expression of CUL1 mRNA |
CTD |
PMID:17895889 |
|
NCBI chr 4:76,551,952...76,625,830
Ensembl chr 4:76,551,983...76,627,980
|
|
G |
Cul3 |
cullin 3 |
decreases expression |
ISO |
Bortezomib results in decreased expression of CUL3 mRNA |
CTD |
PMID:17659339 |
|
NCBI chr 9:81,592,641...81,670,428
Ensembl chr 9:81,592,641...81,670,462
|
|
G |
Cwf19l1 |
CWF19 like cell cycle control factor 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of CWF19L1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:242,997,720...243,020,989
Ensembl chr 1:242,997,726...243,020,961
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
increases expression |
ISO |
Bortezomib results in increased expression of CXCL1 mRNA |
CTD |
PMID:15509775 |
|
NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
increases expression multiple interactions |
ISO EXP |
Bortezomib results in increased expression of CXCL2 mRNA Bortezomib inhibits the reaction [Fluorouracil results in increased expression of CXCL2 mRNA] Bortezomib results in increased expression of CXCL2 mRNA; Bortezomib results in increased expression of CXCL2 protein |
CTD |
PMID:20830808 PMID:27194111 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions increases expression |
ISO |
Bortezomib inhibits the reaction [Fluorouracil results in increased expression of CXCL1 mRNA] Bortezomib results in increased expression of CXCL1 mRNA |
CTD |
PMID:15509775 PMID:27194111 |
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
decreases expression |
ISO |
Bortezomib results in decreased expression of CXCR4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883
|
|
G |
Cyb5r1 |
cytochrome b5 reductase 1 |
increases expression |
ISO |
Bortezomib results in increased expression of CYB5R1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr13:45,849,017...45,855,458
Ensembl chr13:45,849,091...45,855,458
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
decreases expression |
ISO |
Bortezomib results in decreased expression of CYBA mRNA |
CTD |
PMID:20977926 |
|
NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions affects localization |
ISO |
[Bortezomib co-treated with Butyrates] affects the localization of CYCS protein; [Bortezomib co-treated with vorinostat] affects the localization of CYCS protein Bortezomib affects the localization of CYCS protein |
CTD |
PMID:12893773 PMID:16024631 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
affects metabolic processing |
ISO |
CYP1A2 protein affects the metabolism of Bortezomib |
CTD |
PMID:15764713 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
affects metabolic processing |
ISO |
CYP2C19 protein affects the metabolism of Bortezomib |
CTD |
PMID:15764713 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
affects metabolic processing |
ISO |
CYP2D6 protein affects the metabolism of Bortezomib |
CTD |
PMID:15764713 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp2u1 |
cytochrome P450, family 2, subfamily u, polypeptide 1 |
increases expression |
ISO |
Bortezomib results in increased expression of CYP2U1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:219,849,403...219,866,959
Ensembl chr 2:219,849,407...219,866,882
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
affects metabolic processing |
ISO |
CYP3A4 protein affects the metabolism of Bortezomib |
CTD |
PMID:15764713 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cytip |
cytohesin 1 interacting protein |
increases expression |
ISO |
Bortezomib results in increased expression of CYTIP mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:42,698,058...42,774,955
Ensembl chr 3:42,698,768...42,725,993
|
|
G |
Dap3 |
death associated protein 3 |
increases expression |
ISO |
Bortezomib results in increased expression of DAP3 mRNA |
CTD |
PMID:17659339 |
|
NCBI chr 2:174,319,341...174,347,489
Ensembl chr 2:174,318,983...174,346,461
|
|
G |
Dapk2 |
death-associated protein kinase 2 |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DAPK2 mRNA |
CTD |
PMID:25522274 |
|
NCBI chr 8:66,706,536...66,825,567
Ensembl chr 8:66,706,609...66,825,567
|
|
G |
Dazap2 |
DAZ associated protein 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of DAZAP2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:131,714,749...131,720,266
Ensembl chr 7:131,714,745...131,720,265
|
|
G |
Dbn1 |
drebrin 1 |
increases expression |
ISO |
Bortezomib results in increased expression of DBN1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:9,150,608...9,164,982
Ensembl chr17:9,150,659...9,164,984
|
|
G |
Dcaf11 |
DDB1 and CUL4 associated factor 11 |
decreases expression |
ISO |
Bortezomib results in decreased expression of DCAF11 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr15:29,046,744...29,057,450
Ensembl chr15:29,046,826...29,057,669
|
|
G |
Dcaf13 |
DDB1 and CUL4 associated factor 13 |
increases expression |
ISO |
Bortezomib results in increased expression of DCAF13 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:70,160,983...70,196,142
Ensembl chr 7:70,160,941...70,196,142
|
|
G |
Dcps |
decapping enzyme, scavenger |
decreases expression |
ISO |
Bortezomib results in decreased expression of DCPS mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 8:33,468,669...33,524,407
Ensembl chr 8:33,415,671...33,524,389
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions increases expression decreases response to substance |
ISO EXP |
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; [Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein]; Bortezomib inhibits the reaction [Tunicamycin results in increased expression of DDIT3 protein]; Bortezomib promotes the reaction [gambogic acid results in increased expression of DDIT3 protein]; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] affects the localization of CALR protein]; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; DDIT3 protein affects the reaction [Bortezomib affects the localization of CALR protein]; DDIT3 protein affects the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of DDIT3 protein]; gambogic acid promotes the reaction [Bortezomib results in increased expression of DDIT3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased expression of DDIT3 protein] Bortezomib results in increased expression of DDIT3 mRNA; Bortezomib results in increased expression of DDIT3 protein DDIT3 results in decreased susceptibility to Bortezomib 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; [Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein; [Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein]; Bortezomib inhibits the reaction [1,2-dithiol-3-thione inhibits the reaction [Tunicamycin results in increased expression of DDIT3 mRNA]]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]]; Nitroprusside inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Nitroprusside inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein] |
CTD |
PMID:15509775 PMID:16024631 PMID:16357177 PMID:17659339 PMID:17709599 PMID:17898295 PMID:18723477 PMID:20022965 PMID:20110775 PMID:20830808 PMID:22959925 PMID:24291039 PMID:30482226 More...
|
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Ddx11 |
DEAD/H-box helicase 11 |
decreases expression |
ISO |
Bortezomib results in decreased expression of DDX11 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 9:105,833,234...105,862,844
Ensembl chr 9:105,833,504...105,862,550
|
|
G |
Deaf1 |
DEAF1 transcription factor |
decreases expression |
ISO |
Bortezomib results in decreased expression of DEAF1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:196,401,857...196,435,541
Ensembl chr 1:196,401,857...196,435,541
|
|
G |
Dedd2 |
death effector domain containing 2 |
increases expression |
ISO |
Bortezomib results in increased expression of DEDD2 mRNA |
CTD |
PMID:17659339 |
|
NCBI chr 1:80,789,084...80,807,789
Ensembl chr 1:80,792,000...80,807,714
|
|
G |
Def6 |
DEF6 guanine nucleotide exchange factor |
decreases expression |
ISO |
Bortezomib results in decreased expression of DEF6 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr20:6,268,579...6,290,030
Ensembl chr20:6,268,601...6,289,961
|
|
G |
Dennd4a |
DENN domain containing 4A |
increases expression |
ISO |
Bortezomib results in increased expression of DENND4A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 8:65,322,920...65,436,331
Ensembl chr 8:65,322,941...65,436,330
|
|
G |
Dennd4b |
DENN domain containing 4B |
increases expression |
ISO |
Bortezomib results in increased expression of DENND4B mRNA |
CTD |
PMID:15509775 |
|
NCBI chr 2:175,720,473...175,736,425
Ensembl chr 2:175,709,610...175,736,426
|
|
G |
Dennd4c |
DENN domain containing 4C |
increases expression |
ISO |
Bortezomib results in increased expression of DENND4C mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:101,272,298...101,369,529
Ensembl chr 5:101,272,005...101,368,118
|
|
G |
Dgke |
diacylglycerol kinase epsilon |
decreases expression |
ISO |
Bortezomib results in decreased expression of DGKE mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:73,853,030...73,877,334
Ensembl chr10:73,855,583...73,877,100
|
|
G |
Diablo |
diablo, IAP-binding mitochondrial protein |
affects localization increases localization increases expression multiple interactions |
ISO |
Bortezomib affects the localization of DIABLO protein Bortezomib results in increased localization of DIABLO protein Bortezomib results in increased expression of DIABLO mRNA; Bortezomib results in increased expression of DIABLO protein [alvocidib co-treated with Bortezomib] results in increased secretion of DIABLO protein; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in decreased localization of DIABLO protein; [Bortezomib co-treated with Butyrates] affects the localization of DIABLO protein; [Bortezomib co-treated with TNFSF10 protein] results in increased expression of DIABLO protein; [Bortezomib co-treated with vorinostat] affects the localization of DIABLO protein; Bortezomib inhibits the reaction [BAX mutant form inhibits the reaction [TNFSF10 protein results in increased localization of DIABLO protein]]; Bortezomib promotes the reaction [TNFSF10 protein results in increased localization of DIABLO protein] |
CTD |
PMID:12893773 PMID:12902978 PMID:14555532 PMID:15039284 PMID:15070698 PMID:16024631 PMID:17327374 PMID:25913414 More...
|
|
NCBI chr12:33,055,784...33,070,401
Ensembl chr12:33,055,263...33,070,387
|
|
G |
Dlgap5 |
DLG associated protein 5 |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DLGAP5 mRNA |
CTD |
PMID:25522274 |
|
NCBI chr15:20,633,964...20,664,569
Ensembl chr15:20,633,966...20,664,518
|
|
G |
Dnaaf5 |
dynein, axonemal, assembly factor 5 |
decreases expression |
ISO |
Bortezomib results in decreased expression of DNAAF5 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr12:15,453,636...15,492,722
Ensembl chr12:15,453,636...15,492,739
|
|
G |
Dnajb1 |
DnaJ heat shock protein family (Hsp40) member B1 |
increases expression |
ISO |
Bortezomib results in increased expression of DNAJB1 mRNA |
CTD |
PMID:15509775 |
|
NCBI chr19:24,522,731...24,526,419
Ensembl chr19:24,522,717...24,526,458
|
|
G |
Dnajc14 |
DnaJ heat shock protein family (Hsp40) member C14 |
decreases expression |
ISO |
Bortezomib results in decreased expression of DNAJC14 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:1,233,856...1,247,349
Ensembl chr 7:1,235,162...1,248,645
|
|
G |
Dnajc4 |
DnaJ heat shock protein family (Hsp40) member C4 |
decreases expression |
ISO |
Bortezomib results in decreased expression of DNAJC4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:204,178,189...204,182,412
Ensembl chr 1:204,178,191...204,182,387
|
|
G |
Dnm2 |
dynamin 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of DNM2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 8:19,978,313...20,060,162
Ensembl chr 8:19,978,400...20,060,157
|
|
G |
Dpy19l4 |
dpy-19 like 4 |
increases expression |
ISO |
Bortezomib results in increased expression of DPY19L4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:24,351,289...24,410,932
Ensembl chr 5:24,353,900...24,410,912
|
|
G |
Dst |
dystonin |
increases expression |
ISO |
Bortezomib results in increased expression of DST mRNA |
CTD |
PMID:17659339 |
|
NCBI chr 9:36,135,657...36,529,617
Ensembl chr 9:36,135,284...36,529,615
|
|
G |
Dusp15 |
dual specificity phosphatase 15 |
decreases expression |
ISO |
Bortezomib results in decreased expression of DUSP15 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:141,408,495...141,419,137
Ensembl chr 3:141,408,498...141,418,999
|
|
G |
Dusp4 |
dual specificity phosphatase 4 |
decreases expression |
ISO |
Bortezomib results in decreased expression of DUSP4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr16:57,376,659...57,398,161
Ensembl chr16:57,377,229...57,398,138
|
|
G |
Dusp5 |
dual specificity phosphatase 5 |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of DUSP5 mRNA |
CTD |
PMID:25522274 |
|
NCBI chr 1:252,538,408...252,555,320
Ensembl chr 1:252,538,449...252,551,818
|
|
G |
Dync1i1 |
dynein cytoplasmic 1 intermediate chain 1 |
increases expression |
ISO |
Bortezomib results in increased expression of DYNC1I1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:33,852,597...34,166,159
Ensembl chr 4:33,852,927...34,166,149
|
|
G |
E2f1 |
E2F transcription factor 1 |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased activity of E2F1 protein |
CTD |
PMID:25522274 |
|
NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361
|
|
G |
Ecpas |
Ecm29 proteasome adaptor and scaffold |
increases expression |
ISO |
Bortezomib results in increased expression of ECPAS mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:73,601,745...73,714,026
Ensembl chr 5:73,604,533...73,713,860
|
|
G |
Edaradd |
EDAR associated via death domain |
increases expression |
ISO |
Bortezomib results in increased expression of EDARADD mRNA |
CTD |
PMID:17895889 |
|
NCBI chr17:85,866,629...85,910,612
Ensembl chr17:85,656,905...85,910,447
|
|
G |
Egln3 |
egl-9 family hypoxia-inducible factor 3 |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of EGLN3 mRNA |
CTD |
PMID:25522274 |
|
NCBI chr 6:71,650,297...71,675,766
Ensembl chr 6:71,650,297...71,675,766
|
|
G |
Egr1 |
early growth response 1 |
increases expression |
ISO |
Bortezomib results in increased expression of EGR1 mRNA |
CTD |
PMID:20471514 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Egr2 |
early growth response 2 |
decreases expression |
ISO EXP |
Bortezomib results in decreased expression of EGR2 mRNA Bortezomib results in decreased expression of EGR2 mRNA; Bortezomib results in decreased expression of EGR2 protein |
CTD |
PMID:20830808 |
|
NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562
|
|
G |
Ehmt2 |
euchromatic histone lysine methyltransferase 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of EHMT2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr20:3,919,623...3,936,751
Ensembl chr20:3,919,624...3,941,547
|
|
G |
Eif1 |
eukaryotic translation initiation factor 1 |
increases expression |
ISO |
Bortezomib results in increased expression of EIF1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:85,246,751...85,248,842
Ensembl chr10:85,246,764...85,427,327 Ensembl chr 5:85,246,764...85,427,327
|
|
G |
Eif2a |
eukaryotic translation initiation factor 2A |
decreases phosphorylation |
ISO |
Bortezomib results in decreased phosphorylation of EIF2A protein |
CTD |
PMID:18641367 |
|
NCBI chr 2:142,761,303...142,794,767
Ensembl chr 2:142,761,416...142,795,068
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
increases phosphorylation decreases response to substance multiple interactions |
ISO |
Bortezomib results in increased phosphorylation of EIF2AK3 protein EIF2AK3 results in decreased susceptibility to Bortezomib Bortezomib promotes the reaction [ricolinostat results in increased phosphorylation of EIF2AK3 protein]; EIF2AK3 mutant form inhibits the reaction [Bortezomib results in increased phosphorylation of EIF2S1 protein] Bortezomib inhibits the reaction [1,2-dithiol-3-thione inhibits the reaction [Tunicamycin results in increased expression of EIF2AK3 mRNA]] |
CTD |
PMID:15509775 PMID:16928686 PMID:20022965 PMID:22262760 PMID:22959925 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
multiple interactions increases phosphorylation |
ISO |
Bortezomib affects the reaction [ricolinostat results in increased phosphorylation of EIF2S1 protein]; Bortezomib inhibits the reaction [Tunicamycin results in increased phosphorylation of EIF2S1 protein]; EIF2AK3 mutant form inhibits the reaction [Bortezomib results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:16357177 PMID:20022965 PMID:21090173 PMID:22262760 |
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Eif2s3 |
eukaryotic translation initiation factor 2 subunit gamma |
decreases expression |
ISO |
Bortezomib results in decreased expression of EIF2S3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr X:58,916,513...58,939,923
Ensembl chr X:58,917,490...58,940,686
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions |
ISO |
[trichostatin A co-treated with Bortezomib] results in decreased phosphorylation of EIF4EBP1 protein |
CTD |
PMID:21345073 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Eif5a |
eukaryotic translation initiation factor 5A |
decreases expression |
ISO |
Bortezomib results in decreased expression of EIF5A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:54,640,104...54,644,845
Ensembl chr10:54,640,024...54,644,656
|
|
G |
Elp5 |
elongator acetyltransferase complex subunit 5 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ELP5 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:54,692,526...54,704,255
Ensembl chr10:54,692,530...54,704,923
|
|
G |
Eno2 |
enolase 2 |
increases expression |
ISO |
Bortezomib results in increased expression of ENO2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:157,572,085...157,580,971
Ensembl chr 4:157,572,088...157,580,980
|
|
G |
Epha1 |
Eph receptor A1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of EPHA1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:71,246,409...71,260,920
Ensembl chr 4:71,246,409...71,260,846
|
|
G |
Ephb2 |
Eph receptor B2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of EPHB2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:148,889,574...149,077,027
Ensembl chr 5:148,897,246...149,077,059
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions decreases phosphorylation |
ISO |
Bortezomib promotes the reaction [lapatinib results in decreased phosphorylation of ERBB2 protein]; lapatinib promotes the reaction [Bortezomib results in decreased phosphorylation of ERBB2 protein] |
CTD |
PMID:20701607 |
|
NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078
|
|
G |
Ercc3 |
ERCC excision repair 3, TFIIH core complex helicase subunit |
increases response to substance |
ISO |
ERCC3 gene SNP results in increased susceptibility to Bortezomib |
CTD |
PMID:20864405 |
|
NCBI chr18:23,883,613...23,914,326
Ensembl chr18:23,883,580...23,914,329
|
|
G |
Ercc4 |
ERCC excision repair 4, endonuclease catalytic subunit |
increases response to substance |
ISO |
ERCC4 gene SNP results in increased susceptibility to Bortezomib |
CTD |
PMID:20864405 |
|
NCBI chr10:2,416,259...2,448,364
Ensembl chr10:2,419,038...2,448,369 Ensembl chr10:2,419,038...2,448,369
|
|
G |
Erlin2 |
ER lipid raft associated 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ERLIN2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr16:65,017,654...65,034,184
Ensembl chr16:65,018,532...65,033,671
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions decreases response to substance |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ERN1 mRNA; Bortezomib affects the reaction [ricolinostat affects the phosphorylation of ERN1 protein] ERN1 results in decreased susceptibility to Bortezomib |
CTD |
PMID:16357177 PMID:22262760 PMID:25522274 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Esf1 |
ESF1 nucleolar pre-rRNA processing protein homolog |
increases expression |
ISO |
Bortezomib results in increased expression of ESF1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:127,454,744...127,507,941
Ensembl chr 3:127,454,811...127,507,817
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
Bortezomib binds to and results in decreased activity of ESR1 protein; Bortezomib inhibits the reaction [Estradiol results in increased activity of ESR1 protein] |
CTD |
PMID:25752796 PMID:30818834 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
[Arsenic Trioxide co-treated with Bortezomib] results in decreased expression of ESR2 mRNA; Bortezomib binds to and results in decreased activity of ESR2 protein; Bortezomib inhibits the reaction [Estradiol results in increased activity of ESR2 protein] |
CTD |
PMID:25752796 PMID:25913414 PMID:30818834 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Esrra |
estrogen related receptor, alpha |
decreases expression multiple interactions |
ISO |
Bortezomib results in decreased expression of ESRRA mRNA Bortezomib inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein]; Bortezomib inhibits the reaction [XCT790 results in decreased activity of ESRRA protein] |
CTD |
PMID:20977926 PMID:30818834 |
|
NCBI chr 1:204,104,100...204,114,182
Ensembl chr 1:204,104,101...204,114,268
|
|
G |
Esyt2 |
extended synaptotagmin 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ESYT2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:137,219,653...137,312,590
Ensembl chr 6:137,219,707...137,312,590
|
|
G |
Etv4 |
ETS variant transcription factor 4 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ETV4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:86,706,749...86,721,974
Ensembl chr10:86,706,749...86,721,974
|
|
G |
F2rl1 |
F2R like trypsin receptor 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of F2RL1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:26,772,274...26,785,226
Ensembl chr 2:26,772,278...26,785,226
|
|
G |
F3 |
coagulation factor III, tissue factor |
increases expression multiple interactions |
ISO |
Bortezomib results in increased expression of F3 protein [Dexamethasone co-treated with lenalidomide co-treated with Bortezomib] results in increased expression of F3 mRNA; [Dexamethasone co-treated with lenalidomide co-treated with Bortezomib] results in increased expression of F3 protein |
CTD |
PMID:23696885 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Fads2 |
fatty acid desaturase 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of FADS2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789
|
|
G |
Faf1 |
Fas associated factor 1 |
increases expression |
ISO |
Bortezomib results in increased expression of FAF1 mRNA |
CTD |
PMID:17895889 |
|
NCBI chr 5:124,426,032...124,790,014
Ensembl chr 5:124,426,062...124,789,977
|
|
G |
Fam118b |
family with sequence similarity 118, member B |
increases expression |
ISO |
Bortezomib results in increased expression of FAM118B mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 8:33,566,681...33,617,310
Ensembl chr 8:33,566,669...33,617,270
|
|
G |
Fam168a |
family with sequence similarity 168, member A |
increases expression |
ISO |
Bortezomib results in increased expression of FAM168A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:155,057,352...155,203,439
Ensembl chr 1:155,057,352...155,201,220
|
|
G |
Fam20b |
FAM20B, glycosaminoglycan xylosylkinase |
decreases expression |
ISO |
Bortezomib results in decreased expression of FAM20B mRNA |
CTD |
PMID:20977926 |
|
NCBI chr13:68,801,663...68,839,979
Ensembl chr13:68,801,669...68,839,915
|
|
G |
Fam219a |
family with sequence similarity 219, member A |
increases expression |
ISO |
Bortezomib results in increased expression of FAM219A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:56,679,272...56,729,959
Ensembl chr 5:56,680,613...56,729,924
|
|
G |
Fam241b |
family with sequence similarity 241 member B |
increases expression |
ISO |
Bortezomib results in increased expression of FAM241B mRNA |
CTD |
PMID:20977926 |
|
NCBI chr20:30,052,315...30,055,247
Ensembl chr20:30,052,324...30,055,084 Ensembl chr 6:30,052,324...30,055,084
|
|
G |
Fam43a |
family with sequence similarity 43, member A |
decreases expression |
ISO |
Bortezomib results in decreased expression of FAM43A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr11:70,128,253...70,131,401
Ensembl chr11:70,128,253...70,131,401
|
|
G |
Fam76a |
family with sequence similarity 76, member A |
increases expression |
ISO |
Bortezomib results in increased expression of FAM76A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:145,107,491...145,135,734
Ensembl chr 5:145,107,491...145,135,574
|
|
G |
Fancd2 |
FA complementation group D2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of FANCD2 mRNA; Bortezomib results in decreased expression of FANCD2 protein |
CTD |
PMID:19934314 PMID:21917757 |
|
NCBI chr 4:146,679,014...146,743,422
Ensembl chr 4:146,679,179...146,743,412
|
|
G |
Farsa |
phenylalanyl-tRNA synthetase subunit alpha |
decreases expression |
ISO |
Bortezomib results in decreased expression of FARSA mRNA |
CTD |
PMID:20977926 |
|
NCBI chr19:23,291,409...23,300,985
Ensembl chr19:23,268,869...23,300,980
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions increases expression decreases expression |
ISO |
[Bortezomib co-treated with vorinostat] results in increased expression of FAS protein Bortezomib results in increased expression of FAS mRNA; Bortezomib results in increased expression of FAS protein Bortezomib results in decreased expression of FAS mRNA |
CTD |
PMID:17351739 PMID:20471514 PMID:25913414 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
multiple interactions increases expression |
ISO |
[Bortezomib co-treated with vorinostat] results in increased expression of FASLG mRNA; [Bortezomib co-treated with vorinostat] results in increased expression of FASLG protein; Bortezomib promotes the reaction [arsenic trioxide results in increased activity of FASLG]; Curcumin inhibits the reaction [[vorinostat co-treated with Bortezomib] results in increased expression of FASLG protein] Bortezomib results in increased expression of FASLG protein |
CTD |
PMID:17351739 PMID:20471514 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fastk |
Fas-activated serine/threonine kinase |
decreases expression |
ISO |
Bortezomib results in decreased expression of FASTK mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:10,732,273...10,736,332
Ensembl chr 4:10,732,256...10,737,430
|
|
G |
Fbln5 |
fibulin 5 |
decreases expression |
ISO |
Bortezomib results in decreased expression of FBLN5 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:120,899,219...120,977,829
Ensembl chr 6:120,899,224...120,977,755
|
|
G |
Fbxw7 |
F-box and WD repeat domain containing 7 |
decreases expression |
ISO |
Bortezomib results in decreased expression of FBXW7 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:170,149,706...170,311,536
Ensembl chr 2:170,149,694...170,309,941
|
|
G |
Fgf21 |
fibroblast growth factor 21 |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of FGF21 mRNA |
CTD |
PMID:25522274 |
|
NCBI chr 1:96,083,360...96,084,911
Ensembl chr 1:96,083,441...96,090,454
|
|
G |
Fgfr1op2 |
FGFR1 oncogene partner 2 |
increases expression |
ISO |
Bortezomib results in increased expression of FGFR1OP2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:179,491,602...179,512,630
Ensembl chr 4:179,491,599...179,512,630
|
|
G |
Fkbp1a |
FKBP prolyl isomerase 1A |
decreases expression |
ISO |
Bortezomib results in decreased expression of FKBP1A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:140,040,359...140,060,107
Ensembl chr 3:140,040,278...140,060,743
|
|
G |
Fkbp5 |
FKBP prolyl isomerase 5 |
decreases expression |
ISO |
Bortezomib results in decreased expression of FKBP5 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674
|
|
G |
Flcn |
folliculin |
increases expression |
ISO |
Bortezomib results in increased expression of FLCN mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:44,588,621...44,607,808
Ensembl chr10:44,588,624...44,607,769
|
|
G |
Fmr1 |
fragile X messenger ribonucleoprotein 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of FMR1 mRNA |
CTD |
PMID:17659339 |
|
NCBI chr X:147,240,239...147,278,057
Ensembl chr X:147,240,301...147,278,050
|
|
G |
Folr1 |
folate receptor alpha |
decreases expression |
ISO |
Bortezomib results in decreased expression of FOLR1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:156,219,460...156,238,436
Ensembl chr 1:156,219,460...156,230,667
|
|
G |
Foxa1 |
forkhead box A1 |
multiple interactions decreases expression |
ISO |
[arsenic trioxide co-treated with Bortezomib] results in increased expression of FOXA1 mRNA Bortezomib results in decreased expression of FOXA1 mRNA |
CTD |
PMID:20471514 PMID:25913414 |
|
NCBI chr 6:75,099,907...75,136,534
Ensembl chr 6:75,103,503...75,136,188
|
|
G |
Fry |
FRY microtubule binding protein |
increases expression |
ISO |
Bortezomib results in increased expression of FRY mRNA |
CTD |
PMID:20977926 |
|
NCBI chr12:4,493,890...4,887,118
Ensembl chr12:4,493,891...4,799,116
|
|
G |
Fsd1l |
fibronectin type III and SPRY domain containing 1-like |
increases expression |
ISO |
Bortezomib results in increased expression of FSD1L mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:68,258,877...68,334,931
Ensembl chr 5:68,258,932...68,334,928
|
|
G |
Fzd2 |
frizzled class receptor 2 |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of FZD2 mRNA |
CTD |
PMID:25522274 |
|
NCBI chr10:87,561,866...87,563,776
Ensembl chr10:87,561,326...87,565,334
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
decreases expression |
ISO |
Bortezomib results in decreased expression of G6PD mRNA |
CTD |
PMID:20977926 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gabarapl1 |
GABA type A receptor associated protein like 1 |
increases expression |
ISO |
Bortezomib results in increased expression of GABARAPL1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:162,980,309...162,989,452
Ensembl chr 4:162,980,249...162,989,450
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
increases expression multiple interactions |
ISO EXP |
Bortezomib results in increased expression of GADD45A mRNA [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GADD45A mRNA |
CTD |
PMID:20830808 PMID:20977926 PMID:25522274 |
|
NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Gadd45b |
growth arrest and DNA-damage-inducible, beta |
increases expression multiple interactions |
ISO |
Bortezomib results in increased expression of GADD45B mRNA Bortezomib inhibits the reaction [lipopolysaccharide A results in increased expression of GADD45B mRNA] |
CTD |
PMID:15509775 PMID:15797874 PMID:17895889 PMID:17898295 |
|
NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046
|
|
G |
Gadd45g |
growth arrest and DNA-damage-inducible, gamma |
increases expression |
ISO |
Bortezomib results in increased expression of GADD45G mRNA |
CTD |
PMID:17898295 |
|
NCBI chr17:13,376,842...13,378,587
Ensembl chr17:13,376,839...13,378,610
|
|
G |
Galnt4 |
polypeptide N-acetylgalactosaminyltransferase 4 |
increases expression |
ISO |
Bortezomib results in increased expression of GALNT4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:33,925,229...33,927,770
|
|
G |
Ganab |
glucosidase II alpha subunit |
decreases expression |
ISO |
Bortezomib results in decreased expression of GANAB mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:205,793,910...205,813,704
Ensembl chr 1:205,793,895...205,813,695
|
|
G |
Gas7 |
growth arrest specific 7 |
decreases expression |
ISO |
Bortezomib results in decreased expression of GAS7 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:52,152,718...52,383,283
Ensembl chr10:52,152,493...52,383,276
|
|
G |
Gbp2 |
guanylate binding protein 2 |
increases expression |
ISO |
Bortezomib results in increased expression of GBP2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:231,332,488...231,348,573
Ensembl chr 2:231,332,284...231,348,571
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression multiple interactions |
EXP |
Bortezomib results in increased expression of GCLC mRNA Berberine inhibits the reaction [Bortezomib results in increased expression of GCLC mRNA] |
CTD |
PMID:35121005 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression multiple interactions |
EXP |
Bortezomib results in increased expression of GCLM mRNA Berberine inhibits the reaction [Bortezomib results in increased expression of GCLM mRNA] |
CTD |
PMID:35121005 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gcnt2 |
glucosaminyl (N-acetyl) transferase 2 |
increases expression |
ISO |
Bortezomib results in increased expression of GCNT2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:23,796,859...23,901,625
Ensembl chr17:23,796,859...23,901,611
|
|
G |
Gdf15 |
growth differentiation factor 15 |
increases expression multiple interactions |
EXP ISO |
Bortezomib results in increased expression of GDF15 mRNA [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GDF15 mRNA |
CTD |
PMID:20830808 PMID:25522274 |
|
NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055
|
|
G |
Gfap |
glial fibrillary acidic protein |
multiple interactions increases expression |
EXP |
Berberine inhibits the reaction [Bortezomib results in increased expression of GFAP mRNA] |
CTD |
PMID:35121005 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Ghr |
growth hormone receptor |
increases expression |
ISO |
Bortezomib results in increased expression of GHR mRNA |
CTD |
PMID:17895889 |
|
NCBI chr 2:52,541,452...52,804,960
Ensembl chr 2:52,542,594...52,804,735
|
|
G |
Git1 |
GIT ArfGAP 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of GIT1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:62,342,082...62,356,379
Ensembl chr10:62,342,299...62,356,373
|
|
G |
Gkap1 |
G kinase anchoring protein 1 |
increases expression |
ISO |
Bortezomib results in increased expression of GKAP1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:6,383,963...6,423,684
Ensembl chr17:6,383,963...6,423,679
|
|
G |
Gla |
galactosidase, alpha |
increases expression |
ISO |
Bortezomib results in increased expression of GLA mRNA |
CTD |
PMID:20977926 |
|
NCBI chr X:97,769,227...97,780,646
Ensembl chr X:97,768,996...97,780,664
|
|
G |
Glb1 |
galactosidase, beta 1 |
multiple interactions increases expression |
ISO |
TERT protein inhibits the reaction [Bortezomib results in increased expression of GLB1 protein] |
CTD |
PMID:36401358 |
|
NCBI chr 8:114,085,508...114,158,127
Ensembl chr 8:114,085,508...114,158,127
|
|
G |
Gnai3 |
G protein subunit alpha i3 |
increases expression |
ISO |
Bortezomib results in increased expression of GNAI3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:195,742,765...195,780,720
Ensembl chr 2:195,742,642...195,780,742
|
|
G |
Gosr2 |
golgi SNAP receptor complex member 2 |
increases expression |
ISO |
Bortezomib results in increased expression of GOSR2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:88,585,291...88,605,642
Ensembl chr10:88,586,299...88,605,625
|
|
G |
Gpank1 |
G patch domain and ankyrin repeats 1 |
increases expression |
ISO |
Bortezomib results in increased expression of GPANK1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr20:3,697,641...3,700,814
Ensembl chr20:3,697,641...3,700,858
|
|
G |
Gpat3 |
glycerol-3-phosphate acyltransferase 3 |
increases expression |
ISO |
Bortezomib results in increased expression of GPAT3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr14:8,715,367...8,768,051
Ensembl chr14:8,714,373...8,766,490
|
|
G |
Gpatch2l |
G patch domain containing 2-like |
increases expression |
ISO |
Bortezomib results in increased expression of GPATCH2L mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:105,883,383...105,935,644
Ensembl chr 6:105,883,460...105,934,888
|
|
G |
Gphn |
gephyrin |
decreases expression |
ISO |
Bortezomib results in decreased expression of GPHN mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:96,954,365...97,483,617
Ensembl chr 6:96,892,148...97,483,612
|
|
G |
Gpr157 |
G protein-coupled receptor 157 |
decreases expression |
ISO |
Bortezomib results in decreased expression of GPR157 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:160,550,703...160,566,432
Ensembl chr 5:160,550,713...160,566,432
|
|
G |
Gpsm3 |
G-protein signaling modulator 3 |
decreases expression |
ISO |
Bortezomib results in decreased expression of GPSM3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr20:4,157,123...4,158,984
Ensembl chr20:4,157,123...4,159,035
|
|
G |
Gsk3a |
glycogen synthase kinase 3 alpha |
multiple interactions |
ISO |
[Bortezomib co-treated with lonafarnib] results in decreased expression of GSK3A protein modified form |
CTD |
PMID:16118318 |
|
NCBI chr 1:80,815,843...80,825,732
Ensembl chr 1:80,815,850...80,825,802
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
ISO |
[Bortezomib co-treated with lonafarnib] results in decreased expression of GSK3B protein modified form; Bortezomib results in decreased activity of and results in increased phosphorylation of GSK3B protein; GSK3B protein mutant form inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; Wortmannin inhibits the reaction [Bortezomib results in decreased activity of and results in increased phosphorylation of GSK3B protein] |
CTD |
PMID:16118318 PMID:24085292 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gspt1 |
G1 to S phase transition 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of GSPT1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:4,362,528...4,397,215
Ensembl chr10:4,362,510...4,397,198
|
|
G |
Gsr |
glutathione-disulfide reductase |
increases expression |
ISO |
Bortezomib results in increased expression of GSR mRNA |
CTD |
PMID:20977926 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gstcd |
glutathione S-transferase, C-terminal domain containing |
decreases expression |
ISO |
Bortezomib results in decreased expression of GSTCD mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:221,499,732...221,591,888
Ensembl chr 2:221,499,083...221,591,857
|
|
G |
Gstm4 |
glutathione S-transferase mu 4 |
decreases expression |
ISO |
Bortezomib results in decreased expression of GSTM4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:195,667,940...195,685,315
Ensembl chr 2:195,680,004...195,685,323
|
|
G |
Gtf3c2 |
general transcription factor IIIC subunit 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of GTF3C2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:25,196,439...25,221,338
Ensembl chr 6:25,197,268...25,220,490
|
|
G |
Gtpbp1 |
GTP binding protein 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of GTPBP1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:111,248,254...111,272,705
Ensembl chr 7:111,248,254...111,272,705
|
|
G |
Gzma |
granzyme A |
decreases expression |
ISO |
Bortezomib results in decreased expression of GZMA mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:44,740,569...44,752,502
Ensembl chr 2:44,740,569...44,752,493
|
|
G |
Gzmb |
granzyme B |
increases expression |
ISO |
Bortezomib results in increased expression of GZMB mRNA |
CTD |
PMID:20977926 |
|
NCBI chr15:30,343,352...30,346,814
Ensembl chr15:30,173,603...30,346,814
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions decreases phosphorylation increases expression |
ISO EXP |
[Bortezomib co-treated with romidepsin] results in increased phosphorylation of H2AX protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with romidepsin] results in increased phosphorylation of H2AX protein]; leptomycin B promotes the reaction [Bortezomib results in increased expression of H2AX protein modified form] Bortezomib results in decreased phosphorylation of H2AX protein Bortezomib inhibits the reaction [Doxorubicin results in increased expression of H2AX protein]; Bortezomib inhibits the reaction [Etoposide results in increased expression of H2AX protein] |
CTD |
PMID:15173094 PMID:16778179 PMID:17875725 PMID:18790767 PMID:32482060 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239 Ensembl chr 4:44,671,786...44,673,239
|
|
G |
H6pd |
hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase) |
decreases expression |
ISO |
Bortezomib results in decreased expression of H6PD mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:160,434,499...160,470,203
Ensembl chr 5:160,438,697...160,470,171
|
|
G |
Hadha |
hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha |
increases expression |
ISO |
Bortezomib results in increased expression of HADHA mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:26,187,969...26,227,605
Ensembl chr 6:26,187,956...26,227,869
|
|
G |
Haus6 |
HAUS augmin like complex subunit 6 |
increases expression |
ISO |
Bortezomib results in increased expression of HAUS6 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:101,116,532...101,156,396
Ensembl chr 5:101,119,300...101,153,124
|
|
G |
Hdac10 |
histone deacetylase 10 |
decreases expression |
ISO |
Bortezomib results in decreased expression of HDAC10 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:120,199,126...120,205,850
Ensembl chr 7:120,199,129...120,204,228
|
|
G |
Hdac4 |
histone deacetylase 4 |
decreases expression |
ISO |
Bortezomib results in decreased expression of HDAC4 mRNA |
CTD |
PMID:17659339 |
|
NCBI chr 9:92,503,467...92,750,164
Ensembl chr 9:92,507,611...92,750,164
|
|
G |
Hdac6 |
histone deacetylase 6 |
decreases response to substance |
ISO |
HDAC6 results in decreased susceptibility to Bortezomib |
CTD |
PMID:16585204 |
|
NCBI chr X:14,550,645...14,572,445
Ensembl chr X:14,551,044...14,572,441
|
|
G |
Hectd2 |
HECT domain E3 ubiquitin protein ligase 2 |
increases expression |
ISO |
Bortezomib results in increased expression of HECTD2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:234,274,967...234,345,598
Ensembl chr 1:234,275,705...234,343,487
|
|
G |
Hecw1 |
HECT, C2 and WW domain containing E3 ubiquitin protein ligase 1 |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of HECW1 mRNA |
CTD |
PMID:25522274 |
|
NCBI chr17:50,671,239...51,084,536
Ensembl chr17:50,670,954...51,080,720
|
|
G |
Hexd |
hexosaminidase D |
decreases expression |
ISO |
Bortezomib results in decreased expression of HEXD mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:106,479,781...106,498,799
Ensembl chr10:106,480,194...106,498,799
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
increases expression |
ISO |
Bortezomib results in increased expression of HIF1A protein |
CTD |
PMID:16061869 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hikeshi |
heat shock protein nuclear import factor hikeshi |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of HIKESHI mRNA |
CTD |
PMID:25522274 |
|
NCBI chr 1:143,825,399...143,849,361
Ensembl chr 1:143,825,923...143,849,363
|
|
G |
Hist1h2ail1 |
histone cluster 1 H2a family member I like 1 |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of H3C6 mRNA |
CTD |
PMID:25522274 |
|
NCBI chr17:41,568,181...41,569,093
Ensembl chr17:41,568,471...41,569,109
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression increases response to substance |
ISO EXP |
[arsenic trioxide co-treated with Bortezomib] results in decreased expression of HMOX1 mRNA; [cobaltiprotoporphyrin results in increased expression of HMOX1 protein] which results in increased susceptibility to Bortezomib; abexinostat promotes the reaction [Bortezomib results in increased expression of HMOX1 mRNA] Bortezomib results in increased expression of HMOX1 mRNA; Bortezomib results in increased expression of HMOX1 protein HMOX1 protein results in increased susceptibility to Bortezomib Berberine inhibits the reaction [Bortezomib results in increased expression of HMOX1 mRNA] |
CTD |
PMID:15509775 PMID:17895889 PMID:19417023 PMID:20471514 PMID:25913414 PMID:35121005 More...
|
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hmox2 |
heme oxygenase 2 |
multiple interactions |
ISO |
abexinostat promotes the reaction [Bortezomib results in decreased expression of HMOX2 mRNA] |
CTD |
PMID:19417023 |
|
NCBI chr10:10,797,076...10,831,178
Ensembl chr10:10,797,055...10,831,148
|
|
G |
Hnrnpll |
heterogeneous nuclear ribonucleoprotein L-like |
increases expression |
ISO |
Bortezomib results in increased expression of HNRNPLL mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:14,969,953...15,000,574
Ensembl chr 6:14,970,057...14,999,745
|
|
G |
Hoxa11 |
homeobox A11 |
decreases expression |
ISO |
Bortezomib results in decreased expression of HOXA11 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:81,342,527...81,346,189
Ensembl chr 4:81,342,528...81,346,232
|
|
G |
Hps3 |
HPS3, biogenesis of lysosomal organelles complex 2 subunit 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of HPS3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:102,484,574...102,527,580
Ensembl chr 2:102,484,574...102,526,047
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
multiple interactions |
ISO |
ATG5 gene mutant form inhibits the reaction [HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]]; HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein] |
CTD |
PMID:22842577 |
|
NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615
|
|
G |
Hsf1 |
heat shock transcription factor 1 |
increases expression multiple interactions increases activity |
ISO |
Bortezomib results in increased expression of HSF1 mRNA Bortezomib promotes the reaction [HSF1 protein binds to HSPA1A promoter]; HSF1 protein promotes the reaction [Bortezomib results in increased expression of ZFAND2A protein] Bortezomib results in increased activity of HSF1 protein |
CTD |
PMID:17895889 PMID:23874968 PMID:24619424 PMID:31540997 |
|
NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011
|
|
G |
Hsf2 |
heat shock transcription factor 2 |
increases expression multiple interactions |
ISO |
Bortezomib results in increased expression of HSF2 mRNA; Bortezomib results in increased expression of HSF2 protein HSF2 protein inhibits the reaction [Bortezomib results in increased expression of ZFAND2A protein] |
CTD |
PMID:24619424 |
|
NCBI chr20:36,819,864...36,847,490
Ensembl chr20:36,819,864...36,850,174
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
increases expression decreases expression |
ISO EXP |
Bortezomib results in increased expression of HSP90AA1 mRNA Bortezomib results in decreased expression of HSP90AA1 mRNA |
CTD |
PMID:17895889 PMID:20471514 PMID:20830808 |
|
NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268
|
|
G |
Hsp90ab1 |
heat shock protein 90 alpha family class B member 1 |
increases expression |
ISO |
Bortezomib results in increased expression of HSP90AB1 mRNA |
CTD |
PMID:17895889 |
|
NCBI chr 9:15,432,986...15,438,358
Ensembl chr 9:15,433,691...15,438,488
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
multiple interactions decreases response to substance increases expression |
ISO |
Bortezomib promotes the reaction [HSF1 protein binds to HSPA1A promoter] HSPA1A protein results in decreased susceptibility to Bortezomib Bortezomib results in increased expression of HSPA1A mRNA |
CTD |
PMID:17895889 PMID:23874968 |
|
NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227
|
|
G |
Hspa1b |
heat shock protein family A (Hsp70) member 1B |
increases expression decreases response to substance affects response to substance |
ISO |
Bortezomib results in increased expression of HSPA1B mRNA HSPA1B protein results in decreased susceptibility to Bortezomib HSPA1B protein affects the susceptibility to Bortezomib |
CTD |
PMID:15509775 PMID:17895889 PMID:23874968 |
|
NCBI chr20:3,855,104...3,859,148
Ensembl chr20:3,856,006...3,873,240 Ensembl chr20:3,856,006...3,873,240
|
|
G |
Hspa4l |
heat shock protein family A (Hsp70) member 4 like |
increases expression |
EXP |
Bortezomib results in increased expression of HSPA4L mRNA |
CTD |
PMID:20830808 |
|
NCBI chr 2:123,740,384...123,793,088
Ensembl chr 2:123,740,384...123,793,084
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions increases expression decreases response to substance |
ISO |
Bortezomib inhibits the reaction [Brefeldin A results in increased expression of HSPA5 protein]; Bortezomib inhibits the reaction [Tunicamycin results in increased expression of HSPA5 protein]; Bortezomib promotes the reaction [gambogic acid results in increased expression of HSPA5 protein]; Bortezomib promotes the reaction [geldanamycin results in increased expression of HSPA5 protein]; gambogic acid promotes the reaction [Bortezomib results in increased expression of HSPA5 protein]; geldanamycin promotes the reaction [Bortezomib results in increased expression of HSPA5 protein]; MYC protein promotes the reaction [Bortezomib results in increased expression of HSPA5 protein] Bortezomib results in increased expression of HSPA5; Bortezomib results in increased expression of HSPA5 mRNA; Bortezomib results in increased expression of HSPA5 protein HSPA5 results in decreased susceptibility to Bortezomib |
CTD |
PMID:15141013 PMID:15509775 PMID:16024631 PMID:16357177 PMID:18641367 PMID:18723477 PMID:20110775 PMID:20546536 PMID:20977926 PMID:21762082 PMID:24291039 More...
|
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Hspa6l-ps1 |
heat shock protein family A (Hsp70) member 6 like, pseudogene 1 |
increases expression |
ISO |
Bortezomib results in increased expression of HSPA6 mRNA |
CTD |
PMID:15509775 PMID:17898295 PMID:20977926 |
|
NCBI chr13:83,273,176...83,274,317
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
increases expression decreases response to substance |
EXP ISO |
Bortezomib results in increased expression of HSPB1 mRNA HSPB1 protein results in decreased susceptibility to Bortezomib |
CTD |
PMID:14559800 PMID:20830808 |
|
NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743
|
|
G |
Hsph1 |
heat shock protein family H (Hsp110) member 1 |
increases expression |
ISO |
Bortezomib results in increased expression of HSPH1 mRNA |
CTD |
PMID:17898295 |
|
NCBI chr12:5,390,916...5,410,224
Ensembl chr12:5,390,922...5,410,224
|
|
G |
Htr2b |
5-hydroxytryptamine receptor 2B |
decreases expression |
ISO |
Bortezomib results in decreased expression of HTR2B mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 9:86,735,793...86,756,638
Ensembl chr 9:86,742,102...86,755,108
|
|
G |
Htra2 |
HtrA serine peptidase 2 |
affects localization |
ISO |
Bortezomib affects the localization of HTRA2 protein |
CTD |
PMID:16024631 |
|
NCBI chr 4:115,556,914...115,560,202
Ensembl chr 4:115,556,916...115,560,095
|
|
G |
Ibtk |
inhibitor of Bruton tyrosine kinase |
increases expression |
ISO |
Bortezomib results in increased expression of IBTK mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 8:86,625,591...86,698,661
Ensembl chr 8:86,625,597...86,698,260
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions decreases expression |
ISO |
[arsenic trioxide co-treated with Bortezomib] results in decreased expression of ICAM1 mRNA; [romidepsin co-treated with Bortezomib] results in decreased expression of ICAM1 protein Bortezomib results in decreased expression of ICAM1 mRNA |
CTD |
PMID:18223231 PMID:20471514 PMID:25913414 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ide |
insulin degrading enzyme |
increases expression |
ISO |
Bortezomib results in increased expression of IDE mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:235,002,984...235,102,448
Ensembl chr 1:234,995,351...235,102,440
|
|
G |
Idh3a |
isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha |
decreases expression |
ISO |
Bortezomib results in decreased expression of IDH3A mRNA |
CTD |
PMID:30818834 |
|
NCBI chr 8:54,971,694...54,991,085
Ensembl chr 8:54,971,740...54,991,084
|
|
G |
Ifi44 |
interferon-induced protein 44 |
increases expression |
ISO |
Bortezomib results in increased expression of IFI44 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:240,626,058...240,643,879
Ensembl chr 2:240,626,066...240,643,844
|
|
G |
Ifitm1 |
interferon induced transmembrane protein 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of IFITM1 mRNA |
CTD |
PMID:17659339 |
|
NCBI chr 1:196,067,163...196,069,169
Ensembl chr 1:196,067,963...196,069,169
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]] |
CTD |
PMID:30482226 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Ifrd2 |
interferon-related developmental regulator 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of IFRD2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 8:108,260,969...108,266,191
Ensembl chr 8:108,260,969...108,266,194
|
|
G |
Igf1r |
insulin-like growth factor 1 receptor |
increases response to substance |
ISO |
IGF1R gene SNP results in increased susceptibility to Bortezomib |
CTD |
PMID:20864405 |
|
NCBI chr 1:121,549,831...121,838,548
Ensembl chr 1:121,550,743...121,831,777
|
|
G |
Igf2 |
insulin-like growth factor 2 |
multiple interactions decreases response to substance |
ISO |
Bortezomib inhibits the reaction [IGF2 protein results in increased expression of STS mRNA]; Bortezomib inhibits the reaction [IGF2 protein results in increased expression of STS protein] Bortezomib results in decreased susceptibility to IGF2 protein |
CTD |
PMID:24055520 |
|
NCBI chr 1:197,814,409...197,831,802
Ensembl chr 1:197,814,410...197,823,018
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
multiple interactions decreases expression |
ISO |
Bortezomib promotes the reaction [abexinostat results in decreased expression of IKBKB mRNA]; IKBKB protein affects the reaction [Bortezomib results in increased phosphorylation of and results in increased degradation of NFKBIA protein] Bortezomib results in decreased expression of IKBKB mRNA |
CTD |
PMID:19417023 PMID:20471514 PMID:24085292 |
|
NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250
|
|
G |
Ikzf1 |
IKAROS family zinc finger 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of IKZF1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr14:86,255,065...86,340,839
Ensembl chr14:86,255,065...86,342,416
|
|
G |
Il10 |
interleukin 10 |
affects expression |
ISO |
Bortezomib affects the expression of IL10 protein |
CTD |
PMID:19922463 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il15 |
interleukin 15 |
increases expression |
ISO |
Bortezomib results in increased expression of IL15 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr19:25,640,025...25,706,818
Ensembl chr19:25,640,251...25,706,820
|
|
G |
Il18r1 |
interleukin 18 receptor 1 |
increases expression |
ISO |
Bortezomib results in increased expression of IL18R1 mRNA |
CTD |
PMID:17895889 |
|
NCBI chr 9:42,727,416...42,760,971
Ensembl chr 9:42,727,869...42,760,715
|
|
G |
Il1b |
interleukin 1 beta |
increases expression multiple interactions |
EXP |
Bortezomib results in increased expression of IL1B mRNA Berberine inhibits the reaction [Bortezomib results in increased expression of IL1B mRNA] |
CTD |
PMID:35121005 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1r1 |
interleukin 1 receptor type 1 |
increases expression |
ISO |
Bortezomib results in increased expression of IL1R1 mRNA |
CTD |
PMID:17895889 |
|
NCBI chr 9:42,504,917...42,580,958
Ensembl chr 9:42,504,735...42,579,937
|
|
G |
Il23a |
interleukin 23 subunit alpha |
increases expression |
ISO |
Bortezomib results in increased expression of IL23A mRNA |
CTD |
PMID:17895889 |
|
NCBI chr 7:721,809...723,923
Ensembl chr 7:721,809...723,923
|
|
G |
Il6 |
interleukin 6 |
multiple interactions decreases secretion decreases expression increases expression |
ISO EXP |
[Dexamethasone co-treated with Bortezomib] inhibits the reaction [IL6 protein results in increased expression of SOD2 mRNA]; [Dexamethasone co-treated with Bortezomib] results in decreased expression of IL6 mRNA; [Dexamethasone co-treated with Bortezomib] results in decreased secretion of IL6 protein; Bortezomib inhibits the reaction [IL6 protein results in decreased susceptibility to Dexamethasone] Bortezomib results in decreased secretion of IL6 protein Bortezomib results in decreased expression of IL6 mRNA Bortezomib results in increased expression of IL6 mRNA Bortezomib inhibits the reaction [[Chloroquine co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL6 protein]; Bortezomib inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IL6 protein] Berberine inhibits the reaction [Bortezomib results in increased expression of IL6 mRNA] |
CTD |
PMID:17895889 PMID:23063726 PMID:28134560 PMID:35121005 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Il7r |
interleukin 7 receptor |
increases expression multiple interactions |
ISO |
Bortezomib results in increased expression of IL7R mRNA [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of IL7R mRNA |
CTD |
PMID:20471514 PMID:25522274 |
|
NCBI chr 2:58,452,393...58,477,757
Ensembl chr 2:58,454,217...58,477,757
|
|
G |
Ino80b |
INO80 complex subunit B |
decreases expression |
ISO |
Bortezomib results in decreased expression of INO80B mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:115,627,907...115,631,069
Ensembl chr 4:115,627,908...115,631,456
|
|
G |
Irak1 |
interleukin-1 receptor-associated kinase 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of IRAK1 mRNA |
CTD |
PMID:20471514 |
|
NCBI chr X:151,768,621...151,778,521
Ensembl chr X:151,768,777...151,778,521
|
|
G |
Irak2 |
interleukin-1 receptor-associated kinase 2 |
increases expression |
ISO |
Bortezomib results in increased expression of IRAK2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:146,786,004...146,842,615
Ensembl chr 4:146,786,100...146,842,602
|
|
G |
Irf4 |
interferon regulatory factor 4 |
multiple interactions decreases expression |
ISO |
3-(5-(4-(cyclopentyloxy)-2-hydroxybenzoyl)-2-((3-hydroxy-1,2-benzisoxazol-6-yl)methoxy)phenyl)propionic acid promotes the reaction [Bortezomib results in decreased expression of IRF4 protein]; Bortezomib promotes the reaction [3-(5-(4-(cyclopentyloxy)-2-hydroxybenzoyl)-2-((3-hydroxy-1,2-benzisoxazol-6-yl)methoxy)phenyl)propionic acid results in decreased expression of IRF4 protein] |
CTD |
PMID:37657595 |
|
NCBI chr17:33,721,800...33,742,570
Ensembl chr17:33,721,811...33,740,070
|
|
G |
Irs1 |
insulin receptor substrate 1 |
decreases degradation |
ISO |
Bortezomib results in decreased degradation of IRS1 protein |
CTD |
PMID:16227402 |
|
NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122
|
|
G |
Isca1 |
iron-sulfur cluster assembly 1 |
increases expression |
ISO |
Bortezomib results in increased expression of ISCA1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:4,905,291...4,917,955
Ensembl chr17:4,905,287...4,917,955
|
|
G |
Itga6 |
integrin subunit alpha 6 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ITGA6 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:56,604,512...56,689,428
Ensembl chr 3:56,617,268...56,689,428
|
|
G |
Itgal |
integrin subunit alpha L |
decreases expression |
ISO |
Bortezomib results in decreased expression of ITGAL mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:181,918,183...181,955,735
Ensembl chr 1:181,918,183...181,955,732
|
|
G |
Itgav |
integrin subunit alpha V |
multiple interactions increases expression |
ISO |
[arsenic trioxide co-treated with Bortezomib] results in decreased expression of ITGAV mRNA Bortezomib results in increased expression of ITGAV mRNA |
CTD |
PMID:20471514 PMID:25913414 |
|
NCBI chr 3:68,838,514...68,926,653
Ensembl chr 3:68,838,189...68,926,639
|
|
G |
Itgb6 |
integrin subunit beta 6 |
increases expression |
ISO |
Bortezomib results in increased expression of ITGB6 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:45,046,295...45,170,532
Ensembl chr 3:45,048,044...45,121,671
|
|
G |
Jak1 |
Janus kinase 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of JAK1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:115,780,248...115,888,841
Ensembl chr 5:115,780,248...115,888,926
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
decreases expression multiple interactions increases phosphorylation increases expression |
ISO EXP |
Bortezomib results in decreased expression of JUN mRNA [arsenic trioxide co-treated with Bortezomib] results in decreased expression of JUN mRNA; [arsenic trioxide co-treated with Bortezomib] results in increased activity of JUN protein modified form; [Bortezomib co-treated with sorafenib] results in increased phosphorylation of JUN protein; pyrazolanthrone inhibits the reaction [Bortezomib results in increased phosphorylation of JUN protein] Bortezomib results in increased expression of JUN mRNA; Bortezomib results in increased expression of JUN protein; Bortezomib results in increased expression of JUN protein modified form |
CTD |
PMID:12393500 PMID:16357177 PMID:16985072 PMID:17351739 PMID:17495969 PMID:17898295 PMID:20471514 PMID:20830808 PMID:25913414 More...
|
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Junb |
JunB proto-oncogene, AP-1 transcription factor subunit |
decreases expression multiple interactions |
ISO |
Bortezomib results in decreased expression of JUNB protein 3-(5-(4-(cyclopentyloxy)-2-hydroxybenzoyl)-2-((3-hydroxy-1,2-benzisoxazol-6-yl)methoxy)phenyl)propionic acid promotes the reaction [Bortezomib results in decreased expression of JUNB protein]; Bortezomib promotes the reaction [3-(5-(4-(cyclopentyloxy)-2-hydroxybenzoyl)-2-((3-hydroxy-1,2-benzisoxazol-6-yl)methoxy)phenyl)propionic acid results in decreased expression of JUNB protein] |
CTD |
PMID:37657595 |
|
NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035
|
|
G |
Jund |
JunD proto-oncogene, AP-1 transcription factor subunit |
decreases expression |
ISO |
Bortezomib results in decreased expression of JUND mRNA |
CTD |
PMID:20977926 |
|
NCBI chr16:18,734,121...18,735,799
Ensembl chr16:18,734,122...18,735,799
|
|
G |
Kat2b |
lysine acetyltransferase 2B |
decreases expression |
ISO |
Bortezomib results in decreased expression of KAT2B mRNA |
CTD |
PMID:20471514 |
|
NCBI chr 9:6,562,525...6,667,064
Ensembl chr 9:6,562,288...6,667,064
|
|
G |
Kat6b |
lysine acetyltransferase 6B |
decreases expression |
ISO |
Bortezomib results in decreased expression of KAT6B mRNA |
CTD |
PMID:20977926 |
|
NCBI chr15:2,638,885...2,811,977
Ensembl chr15:2,639,200...2,812,316
|
|
G |
Katnal1 |
katanin catalytic subunit A1 like 1 |
increases expression |
ISO |
Bortezomib results in increased expression of KATNAL1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr12:6,094,663...6,156,114
Ensembl chr12:6,102,836...6,157,553
|
|
G |
Kcmf1 |
potassium channel modulatory factor 1 |
increases expression |
ISO |
Bortezomib results in increased expression of KCMF1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:104,888,452...104,950,234
Ensembl chr 4:104,889,847...104,950,234
|
|
G |
Kctd10 |
potassium channel tetramerization domain containing 10 |
increases expression |
ISO |
Bortezomib results in increased expression of KCTD10 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr12:42,230,159...42,248,792
Ensembl chr12:42,230,269...42,248,783
|
|
G |
Kdelr1 |
KDEL endoplasmic reticulum protein retention receptor 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of KDELR1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:96,347,258...96,358,145
Ensembl chr 1:96,347,150...96,358,157
|
|
G |
Kdm4b |
lysine demethylase 4B |
decreases expression |
ISO |
Bortezomib results in decreased expression of KDM4B mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 9:1,158,737...1,237,233
Ensembl chr 9:1,158,752...1,236,543
|
|
G |
Kdm5c |
lysine demethylase 5C |
decreases expression |
ISO |
Bortezomib results in decreased expression of KDM5C mRNA |
CTD |
PMID:20977926 |
|
NCBI chr X:21,345,459...21,387,045
Ensembl chr X:21,345,481...21,381,870
|
|
G |
Kdr |
kinase insert domain receptor |
multiple interactions |
ISO |
[Bortezomib co-treated with sorafenib] results in decreased phosphorylation of KDR protein |
CTD |
PMID:16985072 |
|
NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018
|
|
G |
Kif22 |
kinesin family member 22 |
decreases expression |
ISO |
Bortezomib results in decreased expression of KIF22 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:181,635,347...181,650,351
Ensembl chr 1:181,635,183...181,650,401
|
|
G |
Kif9 |
kinesin family member 9 |
decreases expression |
ISO |
Bortezomib results in decreased expression of KIF9 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 8:110,459,467...110,504,492
Ensembl chr 8:110,459,383...110,505,252
|
|
G |
Kifc1 |
kinesin family member C1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of KIFC1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr20:4,998,832...5,017,107
Ensembl chr20:4,999,047...5,017,105
|
|
G |
Klf6 |
KLF transcription factor 6 |
increases expression |
ISO |
Bortezomib results in increased expression of KLF6 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570
|
|
G |
Klhdc7b |
kelch domain containing 7B |
increases expression |
ISO |
Bortezomib results in increased expression of KLHDC7B mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:120,452,081...120,455,737
Ensembl chr 7:120,453,932...120,455,737
|
|
G |
Klhl20 |
kelch-like family member 20 |
increases expression |
ISO |
Bortezomib results in increased expression of KLHL20 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr13:73,363,451...73,408,293
Ensembl chr13:73,363,455...73,408,337
|
|
G |
Klrk1 |
killer cell lectin like receptor K1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of KLRK1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:163,079,887...163,092,434
Ensembl chr 4:163,081,927...163,092,459
|
|
G |
Kmt2a |
lysine methyltransferase 2A |
multiple interactions |
ISO |
[arsenic trioxide co-treated with Bortezomib] results in decreased expression of KMT2A mRNA |
CTD |
PMID:25913414 |
|
NCBI chr 8:45,116,763...45,193,320
Ensembl chr 8:45,118,814...45,193,181
|
|
G |
Kpna2 |
karyopherin subunit alpha 2 |
increases expression |
ISO |
Bortezomib results in increased expression of KPNA2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:91,933,951...91,946,115
Ensembl chr10:91,933,951...91,946,150
|
|
G |
Kri1 |
KRI1 homolog |
increases expression |
ISO |
Bortezomib results in increased expression of KRI1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 8:19,817,005...19,831,516
Ensembl chr 8:19,817,017...19,831,392
|
|
G |
Krit1 |
KRIT1, ankyrin repeat containing |
increases expression |
ISO |
Bortezomib results in increased expression of KRIT1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:30,299,203...30,333,366
Ensembl chr 4:30,299,203...30,333,359
|
|
G |
Ktn1 |
kinectin 1 |
increases expression |
ISO |
Bortezomib results in increased expression of KTN1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr15:20,913,665...21,002,588
Ensembl chr15:20,914,642...21,002,578
|
|
G |
Lgals2 |
galectin 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of LGALS2 mRNA |
CTD |
PMID:17659339 |
|
NCBI chr 7:110,403,171...110,410,046
Ensembl chr 7:110,403,173...110,404,802
|
|
G |
Lgals8 |
galectin 8 |
increases expression |
ISO |
Bortezomib results in increased expression of LGALS8 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:58,024,652...58,052,764
Ensembl chr17:58,028,105...58,052,764
|
|
G |
Lgr4 |
leucine-rich repeat-containing G protein-coupled receptor 4 |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of LGR4 mRNA |
CTD |
PMID:25522274 |
|
NCBI chr 3:96,447,385...96,550,006
Ensembl chr 3:96,447,858...96,548,899
|
|
G |
Lig4 |
DNA ligase 4 |
increases expression |
ISO |
Bortezomib results in increased expression of LIG4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr16:79,518,393...79,526,956
Ensembl chr16:79,518,312...79,527,040
|
|
G |
Lima1 |
LIM domain and actin binding 1 |
increases expression |
ISO |
Bortezomib results in increased expression of LIMA1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:130,901,717...131,001,512
Ensembl chr 7:130,901,717...131,001,473
|
|
G |
Limd1 |
LIM domain containing 1 |
increases expression |
ISO |
Bortezomib results in increased expression of LIMD1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 8:123,121,363...123,168,476
Ensembl chr 8:123,122,460...123,167,714
|
|
G |
Lims1 |
LIM zinc finger domain containing 1 |
increases expression |
ISO |
Bortezomib results in increased expression of LIMS1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr20:26,309,833...26,418,511
Ensembl chr20:26,309,895...26,418,500
|
|
G |
Lmna |
lamin A/C |
increases cleavage |
ISO |
Bortezomib results in increased cleavage of LMNA protein |
CTD |
PMID:20110775 |
|
NCBI chr 2:173,939,751...173,960,423
Ensembl chr 2:173,939,751...173,960,423
|
|
G |
Lrfn4 |
leucine rich repeat and fibronectin type III domain containing 4 |
decreases expression |
ISO |
Bortezomib results in decreased expression of LRFN4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:201,888,569...201,891,861
Ensembl chr 1:201,888,569...201,891,861
|
|
G |
Lrrc41 |
leucine rich repeat containing 41 |
decreases expression |
ISO |
Bortezomib results in decreased expression of LRRC41 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:129,554,547...129,575,450
Ensembl chr 5:129,554,547...129,575,449
|
|
G |
Lrrfip1 |
LRR binding FLII interacting protein 1 |
increases expression |
ISO |
Bortezomib results in increased expression of LRRFIP1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 9:91,592,032...91,720,250
Ensembl chr 9:91,643,197...91,720,250
|
|
G |
Lsm4 |
LSM4 homolog, U6 small nuclear RNA and mRNA degradation associated |
decreases expression |
ISO |
Bortezomib results in decreased expression of LSM4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr16:18,755,481...18,761,106
Ensembl chr16:18,755,484...18,760,926
|
|
G |
Lst1 |
leukocyte specific transcript 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of LST1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr20:3,634,680...3,639,731
Ensembl chr20:3,634,749...3,637,997
|
|
G |
Luc7l |
LUC7-like |
increases expression |
ISO |
Bortezomib results in increased expression of LUC7L mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:15,273,340...15,307,131
Ensembl chr10:15,273,348...15,303,112
|
|
G |
Ly96 |
lymphocyte antigen 96 |
multiple interactions |
ISO |
[arsenic trioxide co-treated with Bortezomib] results in increased expression of LY96 mRNA |
CTD |
PMID:25913414 |
|
NCBI chr 5:2,582,233...2,612,357
Ensembl chr 5:2,582,254...2,612,386
|
|
G |
Lyn |
LYN proto-oncogene, Src family tyrosine kinase |
multiple interactions |
ISO |
[alvocidib co-treated with Bortezomib co-treated with ABL1 protein] results in decreased phosphorylation of LYN protein |
CTD |
PMID:15039284 |
|
NCBI chr 5:16,639,512...16,755,501
Ensembl chr 5:16,639,466...16,756,868
|
|
G |
Maf1 |
MAF1 homolog, negative regulator of RNA polymerase III |
multiple interactions |
ISO |
Bortezomib inhibits the reaction [Cycloheximide results in increased degradation of MAF1 protein] |
CTD |
PMID:31645432 |
|
NCBI chr 7:108,075,173...108,078,252
Ensembl chr 7:108,075,189...108,078,249
|
|
G |
Mafg |
MAF bZIP transcription factor G |
increases expression |
ISO |
Bortezomib results in increased expression of MAFG mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:105,903,307...105,911,808
Ensembl chr10:105,903,237...105,912,026
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions |
ISO |
MAP1LC3B protein affects the reaction [Bortezomib results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:24085292 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690 Ensembl chr16:49,665,791...49,677,690
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
multiple interactions |
ISO |
[Bortezomib co-treated with Butyrates] results in decreased expression of MAP2K1 protein; [Bortezomib co-treated with vorinostat] results in decreased expression of MAP2K1 protein |
CTD |
PMID:12893773 |
|
NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147
|
|
G |
Map2k2 |
mitogen activated protein kinase kinase 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of MAP2K2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243
|
|
G |
Map2k4 |
mitogen activated protein kinase kinase 4 |
multiple interactions |
ISO |
alvocidib promotes the reaction [Bortezomib results in increased phosphorylation of and results in increased activity of MAP2K4 protein]; Bortezomib results in increased phosphorylation of and results in increased activity of MAP2K4 protein |
CTD |
PMID:15039284 |
|
NCBI chr10:50,343,227...50,447,956
Ensembl chr10:50,344,915...50,447,993
|
|
G |
Map2k6 |
mitogen-activated protein kinase kinase 6 |
decreases expression |
ISO |
Bortezomib results in decreased expression of MAP2K6 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:95,373,304...95,490,406
Ensembl chr10:95,373,204...95,488,293
|
|
G |
Map4k3 |
mitogen-activated protein kinase kinase kinase kinase 3 |
increases expression |
ISO |
Bortezomib results in increased expression of MAP4K3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:14,276,623...14,446,321
Ensembl chr 6:14,277,121...14,446,334
|
|
G |
Map4k4 |
mitogen-activated protein kinase kinase kinase kinase 4 |
increases expression |
ISO |
Bortezomib results in increased expression of MAP4K4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 9:42,200,708...42,326,708
Ensembl chr 9:42,200,278...42,326,698
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions decreases activity increases phosphorylation increases expression |
ISO |
[Bortezomib co-treated with Butyrates] results in decreased expression of MAPK1 protein; [Bortezomib co-treated with panobinostat] results in decreased activity of MAPK1 protein; [Bortezomib co-treated with vorinostat] results in decreased expression of MAPK1 protein; alvocidib inhibits the reaction [Bortezomib results in increased expression of MAPK1 protein modified form]; Bortezomib promotes the reaction [Curcumin results in decreased phosphorylation of MAPK1 protein]; lapatinib inhibits the reaction [Bortezomib results in increased phosphorylation of MAPK1 protein] Bortezomib results in decreased activity of MAPK1 protein |
CTD |
PMID:12893773 PMID:15039284 PMID:18445700 PMID:19383353 PMID:20701607 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk10 |
mitogen activated protein kinase 10 |
multiple interactions |
ISO |
[[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in increased phosphorylation of and results in increased activity of MAPK10 protein; [[Bortezomib co-treated with vorinostat] results in increased abundance of Reactive Oxygen Species] which results in increased phosphorylation of and results in increased activity of MAPK10 protein; [Bortezomib co-treated with Butyrates] results in increased phosphorylation of and results in increased activity of MAPK10 protein; [Bortezomib co-treated with vorinostat] results in increased phosphorylation of and results in increased activity of MAPK10 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in increased phosphorylation of and results in increased activity of MAPK10 protein]; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with vorinostat] results in increased phosphorylation of and results in increased activity of MAPK10 protein] |
CTD |
PMID:15173093 |
|
NCBI chr14:6,497,662...6,790,109
Ensembl chr14:6,497,707...6,786,201
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
ISO |
[Bortezomib co-treated with Butyrates] results in increased phosphorylation of MAPK14 protein; [Bortezomib co-treated with vorinostat] results in increased phosphorylation of MAPK14 protein; MAPK14 mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein] |
CTD |
PMID:12893773 PMID:18790767 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions decreases activity increases phosphorylation increases expression |
ISO |
[Bortezomib co-treated with Butyrates] results in decreased expression of MAPK3 protein; [Bortezomib co-treated with panobinostat] results in decreased activity of MAPK3 protein; [Bortezomib co-treated with vorinostat] results in decreased expression of MAPK3 protein; alvocidib inhibits the reaction [Bortezomib results in increased expression of MAPK3 protein modified form]; Bortezomib promotes the reaction [Curcumin results in decreased phosphorylation of MAPK3 protein]; lapatinib inhibits the reaction [Bortezomib results in increased phosphorylation of MAPK3 protein] Bortezomib results in decreased activity of MAPK3 protein |
CTD |
PMID:12893773 PMID:15039284 PMID:18445700 PMID:19383353 PMID:20701607 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions increases phosphorylation |
ISO EXP |
[[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in increased phosphorylation of and results in increased activity of MAPK8 protein; [[Bortezomib co-treated with vorinostat] results in increased abundance of Reactive Oxygen Species] which results in increased phosphorylation of and results in increased activity of MAPK8 protein; [Bortezomib co-treated with Butyrates] results in increased phosphorylation of and results in increased activity of MAPK8 protein; [Bortezomib co-treated with sorafenib] results in increased phosphorylation of MAPK8 protein; [Bortezomib co-treated with vorinostat] results in increased phosphorylation of and results in increased activity of MAPK8 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in increased phosphorylation of and results in increased activity of MAPK8 protein]; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with vorinostat] results in increased phosphorylation of and results in increased activity of MAPK8 protein]; alvocidib promotes the reaction [Bortezomib results in increased phosphorylation of and results in increased activity of MAPK8 protein]; Bortezomib results in increased phosphorylation of and results in increased activity of MAPK8 protein; CGC 11093 promotes the reaction [Bortezomib results in increased phosphorylation of MAPK8 protein]; MAPK8 results in increased susceptibility to [Bortezomib co-treated with CGC 11093] evodiamine inhibits the reaction [Bortezomib results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:12893773 PMID:15039284 PMID:15173093 PMID:16985072 PMID:18559525 PMID:38010754 More...
|
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
increases phosphorylation multiple interactions |
ISO |
Bortezomib results in increased phosphorylation of MAPK9 protein [Bortezomib co-treated with arsenic trioxide] affects the expression of MAPK9 protein; [Bortezomib co-treated with sorafenib] results in increased phosphorylation of MAPK9 protein; CGC 11093 promotes the reaction [Bortezomib results in increased phosphorylation of MAPK9 protein]; MAPK9 results in increased susceptibility to [Bortezomib co-treated with CGC 11093] |
CTD |
PMID:16985072 PMID:18559525 PMID:18718063 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mapkap1 |
MAPK associated protein 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of MAPKAP1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:17,715,813...17,918,387
Ensembl chr 3:17,715,834...17,918,384
|
|
G |
Mapkapk2 |
MAPK activated protein kinase 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of MAPKAPK2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr13:42,513,762...42,560,061
Ensembl chr13:42,513,762...42,560,457
|
|
G |
Mark2 |
microtubule affinity regulating kinase 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of MARK2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:204,461,029...204,526,247
Ensembl chr 1:204,461,030...204,525,652
|
|
G |
Maz |
MYC associated zinc finger protein |
decreases expression |
ISO |
Bortezomib results in decreased expression of MAZ mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:181,629,742...181,635,193
Ensembl chr 1:181,629,729...181,650,408
|
|
G |
Mbd1 |
methyl-CpG binding domain protein 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of MBD1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr18:67,869,870...67,884,501
Ensembl chr18:67,869,992...67,886,554
|
|
G |
Mbd4 |
methyl-CpG binding domain 4 DNA glycosylase |
increases expression |
ISO |
Bortezomib results in increased expression of MBD4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:148,893,049...148,904,833
Ensembl chr 4:148,894,280...148,904,982
|
|
G |
Mbl2 |
mannose binding lectin 2 |
increases response to substance |
ISO |
MBL2 gene SNP results in increased susceptibility to Bortezomib |
CTD |
PMID:20864405 |
|
NCBI chr 1:228,016,439...228,024,736
|
|
G |
Mbnl1 |
muscleblind-like splicing regulator 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of MBNL1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:144,639,819...144,814,395
Ensembl chr 2:144,670,285...144,814,368
|
|
G |
Mbp |
myelin basic protein |
decreases expression |
ISO |
Bortezomib results in decreased expression of MBP mRNA |
CTD |
PMID:20977926 |
|
NCBI chr18:75,855,878...75,966,404
Ensembl chr18:75,855,878...75,966,404
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
multiple interactions increases expression increases cleavage decreases response to substance |
ISO |
[[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of MCL1 protein; [[Bortezomib co-treated with vorinostat] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of MCL1 protein; [Bortezomib co-treated with Butyrates] results in decreased expression of MCL1 protein; [Bortezomib co-treated with N,N-dimethylsphingosine] results in decreased expression of MCL1 protein; [Bortezomib co-treated with SCIO-469] results in decreased expression of MCL1 protein; [Bortezomib co-treated with SCIO-469] results in decreased expression of MCL1 protein modified form; [Bortezomib co-treated with vorinostat] results in decreased expression of MCL1 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of MCL1 protein]; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with vorinostat] results in decreased expression of MCL1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of MCL1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with vorinostat] results in decreased expression of MCL1 protein]; romidepsin inhibits the reaction [Bortezomib results in increased expression of MCL1 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of MCL1 protein]; TNFSF10 protein inhibits the reaction [Bortezomib results in increased expression of MCL1 protein] Bortezomib results in increased expression of MCL1; Bortezomib results in increased expression of MCL1 protein MCL1 protein results in decreased susceptibility to Bortezomib; MCL1 results in decreased susceptibility to Bortezomib Bortezomib inhibits the reaction [Acetaminophen results in decreased expression of MCL1 protein] |
CTD |
PMID:12893773 PMID:15173093 PMID:16617327 PMID:18223231 PMID:18534018 PMID:18566236 PMID:18625202 PMID:19100720 PMID:20051518 PMID:21195056 PMID:21345073 PMID:25752611 PMID:26769846 More...
|
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Mcm7 |
minichromosome maintenance complex component 7 |
decreases expression |
ISO |
Bortezomib results in decreased expression of MCM7 mRNA |
CTD |
PMID:17659339 |
|
NCBI chr12:17,042,207...17,049,470
Ensembl chr12:17,042,212...17,050,063
|
|
G |
Mdc1 |
mediator of DNA damage checkpoint 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of MDC1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr20:2,893,693...2,912,394
Ensembl chr20:2,895,505...2,910,240
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
multiple interactions increases cleavage affects expression |
ISO |
[CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of MDM2 protein]; Bortezomib promotes the reaction [TP53 protein binds to MDM2 protein] Bortezomib affects the expression of MDM2 protein |
CTD |
PMID:12393500 |
|
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Me1 |
malic enzyme 1 |
increases expression |
ISO |
Bortezomib results in increased expression of ME1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 8:87,549,043...87,660,251
Ensembl chr 8:87,549,043...87,660,304
|
|
G |
Mettl21a |
methyltransferase 21A, HSPA lysine |
increases expression |
ISO |
Bortezomib results in increased expression of METTL21A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 9:65,934,253...65,999,964
Ensembl chr 9:65,978,051...65,987,550
|
|
G |
Mettl27 |
methyltransferase like 27 |
decreases expression |
ISO |
Bortezomib results in decreased expression of METTL27 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr12:21,757,545...21,766,698
Ensembl chr12:21,757,329...21,766,685
|
|
G |
Mex3d |
mex-3 RNA binding family member D |
decreases expression |
ISO |
Bortezomib results in decreased expression of MEX3D mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:9,325,575...9,332,705
Ensembl chr 7:9,325,488...9,332,096
|
|
G |
Mfn1 |
mitofusin 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of MFN1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:115,313,380...115,359,651
Ensembl chr 2:115,313,401...115,359,640
|
|
G |
Mfng |
MFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase |
decreases expression |
ISO |
Bortezomib results in decreased expression of MFNG mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:110,310,810...110,328,653
Ensembl chr 7:110,310,812...110,328,653
|
|
G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
multiple interactions |
ISO |
Bortezomib inhibits the reaction [Disulfiram results in increased degradation of MGMT protein] |
CTD |
PMID:24193513 |
|
NCBI chr 1:191,710,980...191,937,760
Ensembl chr 1:191,710,930...191,937,756
|
|
G |
Mir21 |
microRNA 21 |
increases expression |
ISO |
Bortezomib results in increased expression of MIR21 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:71,405,257...71,405,348
Ensembl chr10:71,405,257...71,405,348
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
decreases expression multiple interactions |
ISO |
Bortezomib results in decreased expression of MKI67 protein [Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]] |
CTD |
PMID:19372569 PMID:30482226 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mllt11 |
MLLT11, transcription factor 7 cofactor |
increases expression |
ISO |
Bortezomib results in increased expression of MLLT11 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:182,795,790...182,804,960
Ensembl chr 2:182,795,790...182,797,199
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
Bortezomib promotes the reaction [butein results in decreased expression of MMP9 protein]; Bortezomib promotes the reaction [capillarisin results in decreased expression of MMP9 protein] |
CTD |
PMID:20696233 PMID:24333736 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mob3a |
MOB kinase activator 3A |
decreases expression |
ISO |
Bortezomib results in decreased expression of MOB3A mRNA |
CTD |
PMID:17659339 |
|
NCBI chr 7:9,010,490...9,027,888
Ensembl chr 7:9,010,587...9,027,879
|
|
G |
Morc2 |
MORC family CW-type zinc finger 2 |
increases expression |
ISO |
Bortezomib results in increased expression of MORC2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr14:78,529,603...78,571,375
Ensembl chr14:78,527,009...78,571,343
|
|
G |
Mpz |
myelin protein zero |
decreases expression |
EXP ISO |
Bortezomib results in decreased expression of MPZ mRNA; Bortezomib results in decreased expression of MPZ protein |
CTD |
PMID:20830808 |
|
NCBI chr13:83,570,811...83,576,680
Ensembl chr13:83,570,811...83,576,679
|
|
G |
Mrpl19 |
mitochondrial ribosomal protein L19 |
increases expression |
ISO |
Bortezomib results in increased expression of MRPL19 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:114,521,824...114,526,053
Ensembl chr 4:114,521,824...114,526,053
|
|
G |
Mrpl30 |
mitochondrial ribosomal protein L30 |
decreases expression |
ISO |
Bortezomib results in decreased expression of MRPL30 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 9:40,125,352...40,136,189
Ensembl chr 9:40,125,430...40,137,257
|
|
G |
Mrps12 |
mitochondrial ribosomal protein S12 |
decreases expression |
ISO |
Bortezomib results in decreased expression of MRPS12 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:84,025,896...84,028,896
Ensembl chr 1:84,025,899...84,028,780
|
|
G |
Mrps5 |
mitochondrial ribosomal protein S5 |
decreases expression |
ISO |
Bortezomib results in decreased expression of MRPS5 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:114,821,046...114,837,291
Ensembl chr 3:114,821,046...114,837,291
|
|
G |
Msh6 |
mutS homolog 6 |
decreases expression |
ISO |
Bortezomib results in decreased expression of MSH6 mRNA |
CTD |
PMID:17659339 |
|
NCBI chr 6:6,562,631...6,579,995
Ensembl chr 6:6,562,632...6,579,956
|
|
G |
Mtmr6 |
myotubularin related protein 6 |
increases expression |
ISO |
Bortezomib results in increased expression of MTMR6 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr15:34,419,931...34,457,863
Ensembl chr15:34,419,903...34,457,861
|
|
G |
Muc1 |
mucin 1, cell surface associated |
decreases expression |
ISO |
Bortezomib results in decreased expression of MUC1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:174,635,989...174,640,738
Ensembl chr 2:174,635,995...174,640,733
|
|
G |
Mutyh |
mutY DNA glycosylase |
decreases expression |
ISO |
Bortezomib results in decreased expression of MUTYH mRNA |
CTD |
PMID:17659339 |
|
NCBI chr 5:130,274,034...130,286,149
Ensembl chr 5:130,274,122...130,286,146
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions decreases expression increases expression |
ISO |
[Bortezomib co-treated with abexinostat] results in decreased expression of MYC mRNA; Bortezomib promotes the reaction [abexinostat results in decreased expression of MYC protein]; MYC protein promotes the reaction [Bortezomib results in increased expression of HSPA5 protein]; MYC protein promotes the reaction [Bortezomib results in increased expression of PMAIP1 protein] Bortezomib results in decreased expression of MYC protein Bortezomib results in increased expression of MYC protein |
CTD |
PMID:12902978 PMID:18641367 PMID:19417023 PMID:20022965 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
decreases expression |
ISO |
Bortezomib results in decreased expression of MYD88 mRNA |
CTD |
PMID:20471514 |
|
NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415
|
|
G |
Myl12a |
myosin light chain 12A |
increases expression |
ISO |
Bortezomib results in increased expression of MYL12A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 9:110,891,970...110,899,655
Ensembl chr 9:110,873,959...110,916,580
|
|
G |
Myo5a |
myosin VA |
increases response to substance |
ISO |
MYO5A gene SNP results in increased susceptibility to Bortezomib |
CTD |
PMID:20864405 |
|
NCBI chr 8:75,811,985...75,980,049
Ensembl chr 8:75,812,412...75,975,918
|
|
G |
Naa80 |
N(alpha)-acetyltransferase 80, NatH catalytic subunit |
decreases expression |
ISO |
Bortezomib results in decreased expression of NAA80 mRNA |
CTD |
PMID:17659339 |
|
NCBI chr 8:108,254,314...108,257,564
Ensembl chr 8:108,253,302...108,257,563
|
|
G |
Nab2 |
Ngfi-A binding protein 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of NAB2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:63,497,589...63,504,105
Ensembl chr 7:63,497,589...63,503,989
|
|
G |
Nabp1 |
nucleic acid binding protein 1 |
increases expression |
ISO |
Bortezomib results in increased expression of NABP1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 9:50,098,552...50,133,982
Ensembl chr 9:50,126,726...50,134,107
|
|
G |
Nadk |
NAD kinase |
decreases expression |
ISO |
Bortezomib results in decreased expression of NADK mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:166,145,708...166,176,328
Ensembl chr 5:166,145,481...166,176,322
|
|
G |
Nadk2 |
NAD kinase 2, mitochondrial |
increases expression |
ISO |
Bortezomib results in increased expression of NADK2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:58,117,674...58,159,815
Ensembl chr 2:58,117,674...58,159,808
|
|
G |
Naf1 |
nuclear assembly factor 1 ribonucleoprotein |
increases expression |
ISO |
Bortezomib results in increased expression of NAF1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr16:22,837,583...22,868,320
Ensembl chr16:22,837,588...22,868,293
|
|
G |
Naip6 |
NLR family, apoptosis inhibitory protein 6 |
affects expression |
ISO |
Bortezomib affects the expression of NAIP mRNA |
CTD |
PMID:25913414 |
|
NCBI chr 2:31,507,423...31,559,098
Ensembl chr 2:31,507,424...31,570,542
|
|
G |
Nap1l2 |
nucleosome assembly protein 1-like 2 |
increases expression |
ISO |
Bortezomib results in increased expression of NAP1L2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr X:68,174,051...68,176,449
Ensembl chr X:68,173,987...68,176,666
|
|
G |
Ncf4 |
neutrophil cytosolic factor 4 |
decreases expression |
ISO |
Bortezomib results in decreased expression of NCF4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:109,825,420...109,843,389
Ensembl chr 7:109,826,020...109,843,389
|
|
G |
Nckap1 |
NCK-associated protein 1 |
increases expression |
ISO |
Bortezomib results in increased expression of NCKAP1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:65,417,450...65,491,769
Ensembl chr 3:65,417,453...65,492,217
|
|
G |
Ncoa3 |
nuclear receptor coactivator 3 |
increases expression |
ISO |
Bortezomib results in increased expression of NCOA3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:154,738,566...154,821,395
Ensembl chr 3:154,738,581...154,818,594
|
|
G |
Ncr1 |
natural cytotoxicity triggering receptor 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of NCR1 protein |
CTD |
PMID:19229052 |
|
NCBI chr 1:69,614,744...69,622,594
Ensembl chr 1:69,616,601...69,660,558
|
|
G |
Ndrg1 |
N-myc downstream regulated 1 |
increases expression |
ISO |
Bortezomib results in increased expression of NDRG1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:98,684,487...98,725,869
Ensembl chr 7:98,684,487...98,725,880
|
|
G |
Ndrg3 |
NDRG family member 3 |
decreases expression |
ISO |
Bortezomib results in decreased expression of NDRG3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:145,587,505...145,650,896
Ensembl chr 3:145,548,041...145,650,873 Ensembl chr 3:145,548,041...145,650,873
|
|
G |
Nedd1 |
NEDD1 gamma-tubulin ring complex targeting factor |
increases expression |
ISO |
Bortezomib results in increased expression of NEDD1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:27,233,050...27,274,486
Ensembl chr 7:27,233,316...27,274,486
|
|
G |
Neto2 |
neuropilin and tolloid like 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of NETO2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr19:21,344,299...21,415,524
Ensembl chr19:21,344,289...21,417,023
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
increases expression increases activity multiple interactions |
ISO EXP |
[Bortezomib results in increased expression of NFE2L2 protein] which results in increased expression of CBR3 mRNA; Bortezomib results in increased expression of NFE2L2 protein Bortezomib results in increased activity of NFE2L2 protein Bortezomib results in increased expression of NFE2L2 mRNA Berberine inhibits the reaction [Bortezomib results in increased expression of NFE2L2 mRNA] |
CTD |
PMID:20806931 PMID:30818834 PMID:35121005 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfia |
nuclear factor I/A |
decreases expression |
ISO |
Bortezomib results in decreased expression of NFIA mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:112,436,655...112,781,878
Ensembl chr 5:112,436,644...112,775,885
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions decreases expression increases expression |
ISO EXP |
[Bortezomib co-treated with vorinostat] results in decreased activity of [NFKB1 protein binds to RELA protein]; [resveratrol co-treated with Bortezomib] results in decreased activity of [RELA protein binds to NFKB1 protein]; Bortezomib inhibits the reaction [belinostat results in increased expression of NFKB1 protein]; Bortezomib inhibits the reaction [romidepsin results in increased expression of NFKB1 protein]; Bortezomib promotes the reaction [Fenretinide inhibits the reaction [TNF protein results in increased activity of NFKB1 protein]] Bortezomib results in decreased expression of NFKB1 mRNA; Bortezomib results in decreased expression of NFKB1 protein Berberine inhibits the reaction [Bortezomib results in increased expression of NFKB1 mRNA] |
CTD |
PMID:12893773 PMID:16230421 PMID:17164350 PMID:17626072 PMID:18223231 PMID:25913414 PMID:35121005 More...
|
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkb2 |
nuclear factor kappa B subunit 2 |
decreases cleavage decreases expression |
ISO |
Bortezomib results in decreased cleavage of NFKB2 protein Bortezomib results in decreased expression of NFKB2 mRNA; Bortezomib results in decreased expression of NFKB2 protein |
CTD |
PMID:17626072 PMID:18223231 PMID:25913414 |
|
NCBI chr 1:245,164,586...245,173,225
Ensembl chr 1:245,165,950...245,173,213
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions decreases degradation increases expression increases degradation increases stability increases phosphorylation |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; [Bortezomib co-treated with Arsenic Trioxide] affects the expression of NFKBIA protein; [Bortezomib co-treated with TNFSF10 protein] inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; [Dexamethasone co-treated with Bortezomib] results in increased expression of NFKBIA mRNA; [Dexamethasone co-treated with Bortezomib] results in increased phosphorylation of NFKBIA protein; alvocidib promotes the reaction [Bortezomib results in increased expression of NFKBIA protein modified form]; Ammonium Chloride inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; Bortezomib inhibits the reaction [belinostat results in increased expression of NFKBIA protein]; Bortezomib inhibits the reaction [romidepsin results in increased expression of NFKBIA protein]; Bortezomib promotes the reaction [alvocidib results in increased expression of NFKBIA protein modified form]; Bortezomib results in increased phosphorylation of and results in increased degradation of NFKBIA protein; Chloroquine inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; Dexamethasone inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; GSK3B protein mutant form inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; IKBKB protein affects the reaction [Bortezomib results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; MAP1LC3B protein affects the reaction [Bortezomib results in increased phosphorylation of NFKBIA protein]; NFKBIA protein mutant form inhibits the reaction [Bortezomib results in increased expression of PTGS2 protein]; SC 514 affects the reaction [Bortezomib results in increased phosphorylation of NFKBIA protein]; SC 514 inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; Wortmannin inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein] Bortezomib results in decreased degradation of NFKBIA protein Bortezomib results in increased expression of NFKBIA mRNA; Bortezomib results in increased expression of NFKBIA protein modified form Bortezomib results in increased stability of NFKBIA protein |
CTD |
PMID:15039284 PMID:15543232 PMID:17895889 PMID:18089816 PMID:18223231 PMID:18718063 PMID:19261616 PMID:23063726 PMID:24085292 More...
|
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nfkbib |
NFKB inhibitor beta |
increases stability increases expression |
ISO |
Bortezomib results in increased stability of NFKBIB protein Bortezomib results in increased expression of NFKBIB mRNA |
CTD |
PMID:15543232 PMID:20977926 PMID:25913414 |
|
NCBI chr 1:84,046,292...84,053,862
Ensembl chr 1:84,046,295...84,053,862
|
|
G |
Nfkbie |
NFKB inhibitor epsilon |
multiple interactions increases stability |
ISO |
Bortezomib inhibits the reaction [arsenic trioxide results in decreased expression of NFKBIE mRNA] Bortezomib results in increased stability of NFKBIE protein |
CTD |
PMID:15543232 PMID:20471514 |
|
NCBI chr 9:15,443,600...15,450,437
Ensembl chr 9:15,436,941...15,450,437
|
|
G |
Nfyc |
nuclear transcription factor Y subunit gamma |
decreases expression |
ISO |
Bortezomib results in decreased expression of NFYC mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:134,336,802...134,405,372
Ensembl chr 5:134,336,808...134,405,377
|
|
G |
Nipsnap1 |
nipsnap homolog 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of NIPSNAP1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr14:79,734,234...79,758,101
Ensembl chr14:79,734,209...79,758,098
|
|
G |
Nlrp12 |
NLR family, pyrin domain containing 12 |
multiple interactions increases expression |
ISO |
Bortezomib promotes the reaction [arsenic trioxide results in increased expression of NLRP12 mRNA] Bortezomib results in increased expression of NLRP12 mRNA |
CTD |
PMID:20471514 |
|
NCBI chr 1:65,932,610...65,969,873
Ensembl chr 1:65,932,595...65,960,934
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
decreases expression increases expression multiple interactions |
ISO EXP |
Bortezomib results in decreased expression of NLRP3 mRNA Bortezomib results in increased expression of NLRP3 mRNA Berberine inhibits the reaction [Bortezomib results in increased expression of NLRP3 mRNA] |
CTD |
PMID:17659339 PMID:35121005 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Nos1 |
nitric oxide synthase 1 |
increases expression multiple interactions |
ISO |
Bortezomib results in increased expression of NOS1 protein Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of NOS1 protein] |
CTD |
PMID:30482226 |
|
NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945
|
|
G |
Notch2 |
notch receptor 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of NOTCH2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:185,610,594...185,744,088
Ensembl chr 2:185,610,589...185,744,088
|
|
G |
Npm1 |
nucleophosmin 1 |
multiple interactions increases response to substance affects response to substance |
ISO |
Acetylcysteine inhibits the reaction [NPM1 protein mutant form results in increased susceptibility to Bortezomib] NPM1 protein affects the susceptibility to Bortezomib |
CTD |
PMID:23877794 |
|
NCBI chr10:17,741,512...17,751,626
Ensembl chr10:17,739,941...17,751,645 Ensembl chr X:17,739,941...17,751,645
|
|
G |
Nptx1 |
neuronal pentraxin 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of NPTX1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:104,811,107...104,820,358
Ensembl chr10:104,811,403...104,820,367
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression multiple interactions |
ISO EXP |
Bortezomib results in increased expression of NQO1 mRNA Berberine inhibits the reaction [Bortezomib results in increased expression of NQO1 mRNA] |
CTD |
PMID:20977926 PMID:35121005 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nqo2 |
N-ribosyldihydronicotinamide:quinone dehydrogenase 2 |
increases expression |
ISO |
Bortezomib results in increased expression of NQO2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:30,909,482...30,938,725
Ensembl chr17:30,909,187...30,938,320
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
decreases expression |
ISO |
Bortezomib results in decreased expression of NR1H3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
ISO |
Bortezomib inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein] |
CTD |
PMID:25257666 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions |
ISO |
Bortezomib inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of NR1I3 protein] |
CTD |
PMID:30818834 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Nrip3 |
nuclear receptor interacting protein 3 |
increases expression |
EXP |
Bortezomib results in increased expression of NRIP3 mRNA |
CTD |
PMID:20830808 |
|
NCBI chr 1:163,789,738...163,815,036
Ensembl chr 1:163,789,738...163,815,600
|
|
G |
Ns5atp4 |
NS5A transactivated protein 4 |
decreases expression |
ISO |
Bortezomib results in decreased expression of C1ORF43 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:175,494,406...175,507,281
Ensembl chr 2:175,494,304...175,510,663
|
|
G |
Nt5c2 |
5'-nucleotidase, cytosolic II |
increases expression |
ISO |
Bortezomib results in increased expression of NT5C2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:245,770,993...245,896,925
Ensembl chr 1:245,772,277...245,897,913
|
|
G |
Nt5e |
5' nucleotidase, ecto |
decreases expression |
ISO |
Bortezomib results in decreased expression of NT5E mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 8:89,271,046...89,314,918
Ensembl chr 8:89,270,696...89,314,881
|
|
G |
Nub1 |
negative regulator of ubiquitin-like proteins 1 |
increases expression |
ISO |
Bortezomib results in increased expression of NUB1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:10,442,917...10,473,689
Ensembl chr 4:10,442,917...10,473,694
|
|
G |
Nucks1 |
nuclear casein kinase and cyclin-dependent kinase substrate 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of NUCKS1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr13:43,345,091...43,374,316
Ensembl chr13:43,345,115...43,370,229
|
|
G |
Numb |
NUMB, endocytic adaptor protein |
increases expression |
ISO |
Bortezomib results in increased expression of NUMB mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:103,431,400...103,553,422
Ensembl chr 6:103,431,400...103,553,354
|
|
G |
Numbl |
NUMB-like, endocytic adaptor protein |
increases expression |
ISO |
Bortezomib results in increased expression of NUMBL mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:82,549,814...82,573,788
Ensembl chr 1:82,550,054...82,573,776
|
|
G |
Nupr1 |
nuclear protein 1, transcriptional regulator |
multiple interactions increases expression |
ISO |
NUPR1 mutant form promotes the reaction [Bortezomib results in increased expression of ATF4 mRNA] Bortezomib results in increased expression of NUPR1 mRNA |
CTD |
PMID:20022965 |
|
NCBI chr 1:181,213,292...181,215,327
Ensembl chr 1:181,213,368...181,215,281
|
|
G |
Nxpe3 |
neurexophilin and PC-esterase domain family, member 3 |
increases expression |
ISO |
Bortezomib results in increased expression of NXPE3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr11:44,726,905...44,777,694
Ensembl chr11:44,727,069...44,777,694
|
|
G |
Obscn |
obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF |
decreases expression |
ISO |
Bortezomib results in decreased expression of OBSCN mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:43,774,113...43,919,718
Ensembl chr10:43,789,293...43,919,723
|
|
G |
Ogdh |
oxoglutarate dehydrogenase |
decreases expression |
ISO |
Bortezomib results in decreased expression of OGDH mRNA |
CTD |
PMID:20977926 |
|
NCBI chr14:81,150,021...81,217,479
Ensembl chr14:81,150,091...81,217,479
|
|
G |
Ogfr |
opioid growth factor receptor |
decreases expression |
ISO |
Bortezomib results in decreased expression of OGFR mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:167,703,173...167,709,459
Ensembl chr 3:167,702,695...167,709,473
|
|
G |
Ogt |
O-linked N-acetylglucosamine (GlcNAc) transferase |
decreases expression |
ISO |
Bortezomib results in decreased expression of OGT mRNA |
CTD |
PMID:20977926 |
|
NCBI chr X:66,771,278...66,816,148
Ensembl chr X:66,771,349...66,816,146
|
|
G |
Orai2 |
ORAI calcium release-activated calcium modulator 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ORAI2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr12:20,500,308...20,520,428
Ensembl chr12:20,497,317...20,520,428
|
|
G |
Os9 |
OS9, endoplasmic reticulum lectin |
increases expression |
ISO |
Bortezomib results in increased expression of OS9 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:62,915,498...62,957,591
Ensembl chr 7:62,915,515...62,943,745
|
|
G |
Osbpl2 |
oxysterol binding protein-like 2 |
increases expression |
ISO |
Bortezomib results in increased expression of OSBPL2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:167,210,945...167,256,219
Ensembl chr 3:167,210,832...167,256,219
|
|
G |
Osgin1 |
oxidative stress induced growth inhibitor 1 |
increases expression |
ISO EXP |
Bortezomib results in increased expression of OSGIN1 mRNA |
CTD |
PMID:20830808 PMID:20977926 |
|
NCBI chr19:47,471,750...47,500,517
Ensembl chr19:47,492,171...47,500,516
|
|
G |
Pacsin1 |
protein kinase C and casein kinase substrate in neurons 1 |
increases expression |
ISO |
Bortezomib results in increased expression of PACSIN1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr20:5,718,134...5,768,064
Ensembl chr20:5,719,857...5,765,313
|
|
G |
Palld |
palladin, cytoskeletal associated protein |
increases expression |
ISO |
Bortezomib results in increased expression of PALLD mRNA |
CTD |
PMID:20977926 |
|
NCBI chr16:28,228,006...28,621,349
Ensembl chr16:27,981,354...28,621,337
|
|
G |
Panx2 |
pannexin 2 |
increases expression |
ISO |
Bortezomib results in increased expression of PANX2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:120,139,259...120,153,056
Ensembl chr 7:120,139,294...120,152,361
|
|
G |
Papola |
poly (A) polymerase alpha |
decreases expression |
ISO |
Bortezomib results in decreased expression of PAPOLA mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:124,682,015...124,734,706
Ensembl chr 6:124,682,105...124,734,468
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage increases expression |
ISO |
[alvocidib co-treated with Bortezomib] results in increased cleavage of PARP1 protein; [Arsenic Trioxide co-treated with Bortezomib] results in increased degradation of PARP1 protein; [Bortezomib co-treated with abexinostat] results in increased activity of PARP1 protein; [Bortezomib co-treated with Butyrates] results in increased degradation of PARP1 protein; [Bortezomib co-treated with Doxorubicin] results in increased cleavage of PARP1 protein; [Bortezomib co-treated with N,N-dimethylsphingosine] results in increased cleavage of PARP1 protein; [Bortezomib co-treated with Sorafenib] results in increased cleavage of PARP1 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of PARP1 protein; [Bortezomib co-treated with Vorinostat] results in increased degradation of PARP1 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of PARP1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein; [Curcumin co-treated with Bortezomib] results in increased cleavage of PARP1 protein; [Dichlororibofuranosylbenzimidazole co-treated with Bortezomib] results in increased cleavage of PARP1 protein; [RB1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of PARP1 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [Bortezomib promotes the reaction [gambogic acid results in increased cleavage of PARP1 protein]]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [gambogic acid promotes the reaction [Bortezomib results in increased cleavage of PARP1 protein]]; Bortezomib promotes the reaction [belinostat results in increased cleavage of PARP1 protein]; Bortezomib promotes the reaction [capillarisin results in increased cleavage of PARP1 protein]; Bortezomib promotes the reaction [gambogic acid results in increased cleavage of PARP1 protein]; Bortezomib promotes the reaction [romidepsin results in increased cleavage of PARP1 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of PARP1 protein]; Bortezomib results in increased cleavage of and results in increased activity of PARP1 protein; gambogic acid promotes the reaction [Bortezomib results in increased cleavage of PARP1 protein]; ricolinostat promotes the reaction [Bortezomib results in increased cleavage of PARP1 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of PARP1 protein]; TNFRSF10B mutant form inhibits the reaction [Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]]; TNFRSF10B mutant form inhibits the reaction [Bortezomib results in increased cleavage of PARP1 protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased cleavage of PARP1 protein]; TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein]; ZFAND2A protein inhibits the reaction [Bortezomib results in increased cleavage of PARP1 protein] Bortezomib results in increased expression of PARP1 protein |
CTD |
PMID:12893773 PMID:12902978 PMID:15039284 PMID:16617327 PMID:16904634 PMID:16985072 PMID:17156654 PMID:17326159 PMID:17495969 PMID:17510429 PMID:17659339 PMID:17898295 PMID:17898787 PMID:18223231 PMID:18723477 PMID:18790767 PMID:19261616 PMID:19372569 PMID:19417023 PMID:20110775 PMID:20383943 PMID:20461078 PMID:21195056 PMID:22262760 PMID:24291039 PMID:24333736 PMID:25522274 PMID:29384525 PMID:31540997 PMID:33775688 More...
|
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Parp6 |
poly (ADP-ribose) polymerase family, member 6 |
decreases expression |
ISO |
Bortezomib results in decreased expression of PARP6 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 8:60,016,594...60,049,108
Ensembl chr 8:60,016,877...60,049,108
|
|
G |
Patz1 |
POZ (BTB) and AT hook containing zinc finger 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of PATZ1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr14:78,154,590...78,173,032
Ensembl chr14:78,152,516...78,173,032
|
|
G |
Pawr |
pro-apoptotic WT1 regulator |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of PAWR mRNA |
CTD |
PMID:25522274 |
|
NCBI chr 7:43,645,028...43,725,033
Ensembl chr 7:43,645,084...43,725,028
|
|
G |
Pbx3 |
PBX homeobox 3 |
decreases expression |
ISO |
Bortezomib results in decreased expression of PBX3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:17,488,691...17,682,412
Ensembl chr 3:17,488,693...17,682,791
|
|
G |
Pcgf3 |
polycomb group ring finger 3 |
increases expression |
ISO |
Bortezomib results in increased expression of PCGF3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr14:1,237,594...1,291,717
Ensembl chr14:1,233,947...1,291,793
|
|
G |
Pcnx4 |
pecanex 4 |
increases expression |
ISO |
Bortezomib results in increased expression of PCNX4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:91,125,063...91,170,423
Ensembl chr 6:91,125,063...91,170,439
|
|
G |
Pcyt1a |
phosphate cytidylyltransferase 1A, choline |
increases expression multiple interactions |
ISO |
Bortezomib results in increased expression of PCYT1A mRNA [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of PCYT1A mRNA |
CTD |
PMID:20977926 PMID:25522274 |
|
NCBI chr11:68,313,860...68,357,828
Ensembl chr11:68,313,882...68,357,357
|
|
G |
Pdcl |
phosducin like |
increases expression |
ISO |
Bortezomib results in increased expression of PDCL mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:21,110,165...21,119,763
Ensembl chr 3:21,110,167...21,119,715 Ensembl chr 3:21,110,167...21,119,715
|
|
G |
Pde7a |
phosphodiesterase 7A |
decreases expression |
ISO |
Bortezomib results in decreased expression of PDE7A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:101,714,767...101,806,853
Ensembl chr 2:101,718,444...101,806,681
|
|
G |
Pdgfrb |
platelet derived growth factor receptor beta |
multiple interactions |
ISO |
[Bortezomib co-treated with sorafenib] results in decreased phosphorylation of PDGFRB protein |
CTD |
PMID:16985072 |
|
NCBI chr18:54,499,962...54,538,840
Ensembl chr18:54,499,964...54,538,843
|
|
G |
Pdk2 |
pyruvate dehydrogenase kinase 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of PDK2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:79,972,550...79,987,074
Ensembl chr10:79,972,556...79,987,085
|
|
G |
Pfdn4 |
prefoldin subunit 4 |
increases expression |
ISO |
Bortezomib results in increased expression of PFDN4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:159,303,173...159,311,221
Ensembl chr 3:159,303,071...159,311,219
|
|
G |
Pgr |
progesterone receptor |
multiple interactions |
ISO |
Bortezomib binds to and results in decreased activity of PGR protein; Bortezomib inhibits the reaction [Promegestone results in increased activity of PGR protein] |
CTD |
PMID:25752796 PMID:30818834 |
|
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Phc3 |
polyhomeotic homolog 3 |
increases expression |
ISO |
Bortezomib results in increased expression of PHC3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:112,408,709...112,483,719
Ensembl chr 2:112,408,531...112,476,540
|
|
G |
Phf1 |
PHD finger protein 1 |
increases expression |
ISO |
Bortezomib results in increased expression of PHF1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr20:5,017,765...5,022,872
Ensembl chr20:5,017,893...5,022,871
|
|
G |
Phkb |
phosphorylase kinase regulatory subunit beta |
increases expression |
ISO |
Bortezomib results in increased expression of PHKB mRNA |
CTD |
PMID:20977926 |
|
NCBI chr19:21,013,719...21,210,671
Ensembl chr19:21,025,733...21,210,633
|
|
G |
Phlda1 |
pleckstrin homology-like domain, family A, member 1 |
increases expression |
ISO |
Bortezomib results in increased expression of PHLDA1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:46,967,433...46,969,637
Ensembl chr 7:46,967,409...46,969,861
|
|
G |
Phtf1 |
putative homeodomain transcription factor 1 |
increases expression |
ISO |
Bortezomib results in increased expression of PHTF1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:191,470,849...191,537,399
Ensembl chr 2:191,473,130...191,512,078
|
|
G |
Pi4kb |
phosphatidylinositol 4-kinase beta |
decreases expression |
ISO |
Bortezomib results in decreased expression of PI4KB mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:182,540,377...182,572,684
Ensembl chr 2:182,540,567...182,588,488
|
|
G |
Pip4p1 |
phosphatidylinositol-4,5-bisphosphate 4-phosphatase 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of PIP4P1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr15:24,146,854...24,150,739
Ensembl chr15:24,146,856...24,150,702
|
|
G |
Pip5k1a |
phosphatidylinositol-4-phosphate 5-kinase, type 1, alpha |
decreases expression |
ISO |
Bortezomib results in decreased expression of PIP5K1A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:182,628,299...182,671,584
Ensembl chr 2:182,628,300...182,671,598
|
|
G |
Pir |
pirin |
increases expression |
ISO |
Bortezomib results in increased expression of PIR mRNA |
CTD |
PMID:20977926 |
|
NCBI chr X:30,108,536...30,219,269
Ensembl chr X:30,108,538...30,219,218
|
|
G |
Pkia |
cAMP-dependent protein kinase inhibitor alpha |
increases expression |
ISO |
Bortezomib results in increased expression of PKIA mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:94,398,869...94,473,638
Ensembl chr 2:94,398,869...94,414,282
|
|
G |
Plaa |
phospholipase A2, activating protein |
increases expression |
ISO |
Bortezomib results in increased expression of PLAA mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:109,428,600...109,460,373
Ensembl chr 5:109,428,265...109,460,282
|
|
G |
Plekhm2 |
pleckstrin homology and RUN domain containing M2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of PLEKHM2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:153,939,582...153,978,625
Ensembl chr 5:153,940,262...153,978,689
|
|
G |
Pm20d2 |
peptidase M20 domain containing 2 |
increases expression |
ISO |
Bortezomib results in increased expression of PM20D2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:47,566,059...47,586,334
Ensembl chr 5:47,566,072...47,586,212
|
|
G |
Pmaip1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
multiple interactions increases response to substance increases expression decreases expression |
ISO |
[arsenic trioxide co-treated with Bortezomib] results in decreased expression of PMAIP1 mRNA; [Bortezomib co-treated with arsenic trioxide] results in increased expression of PMAIP1 protein; [Bortezomib co-treated with vorinostat] results in increased expression of PMAIP1 protein; [nutlin 3 co-treated with Bortezomib] results in increased expression of PMAIP1 protein; ATF3 mutant form promotes the reaction [Bortezomib results in increased expression of PMAIP1 mRNA]; ATF4 mutant form inhibits the reaction [Bortezomib results in increased expression of PMAIP1 mRNA]; ATF4 mutant form inhibits the reaction [Bortezomib results in increased expression of PMAIP1 protein]; Bortezomib promotes the reaction [ATF4 protein binds to PMAIP1 promoter]; MYC protein promotes the reaction [Bortezomib results in increased expression of PMAIP1 protein]; PMAIP1 protein promotes the reaction [[Bortezomib co-treated with arsenic trioxide] results in increased activity of CASP3 protein]; PMAIP1 protein promotes the reaction [[Bortezomib co-treated with vorinostat] results in increased activity of CASP4 protein] PMAIP1 protein results in increased susceptibility to Bortezomib; PMAIP1 results in increased susceptibility to Bortezomib Bortezomib results in increased expression of PMAIP1 mRNA; Bortezomib results in increased expression of PMAIP1 protein Bortezomib results in decreased expression of PMAIP1 mRNA |
CTD |
PMID:16024631 PMID:16166592 PMID:16928686 PMID:17898295 PMID:18534018 PMID:18641367 PMID:18790767 PMID:20022965 PMID:20051518 PMID:20850924 PMID:20977926 PMID:21518486 PMID:25913414 More...
|
|
NCBI chr18:59,986,020...59,992,434
Ensembl chr18:59,986,017...59,992,429
|
|
G |
Pml |
PML nuclear body scaffold |
multiple interactions |
ISO |
Bortezomib inhibits the reaction [Arsenic results in increased degradation of PML protein] |
CTD |
PMID:36880596 |
|
NCBI chr 8:58,627,347...58,661,927
Ensembl chr 8:58,628,837...58,658,971
|
|
G |
Pnisr |
PNN interacting serine and arginine rich protein |
increases expression |
ISO |
Bortezomib results in increased expression of PNISR mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:35,395,965...35,422,852
Ensembl chr 5:35,395,965...35,422,844
|
|
G |
Pnmt |
phenylethanolamine-N-methyltransferase |
decreases expression |
ISO |
Bortezomib results in decreased expression of PNMT mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:83,383,019...83,386,557
Ensembl chr10:83,384,923...83,386,556
|
|
G |
Pno1 |
partner of NOB1 homolog |
increases expression |
ISO |
Bortezomib results in increased expression of PNO1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr14:91,609,711...91,618,280
Ensembl chr14:91,609,233...91,618,324
|
|
G |
Poc1b |
POC1 centriolar protein B |
increases expression |
ISO |
Bortezomib results in increased expression of POC1B mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:33,924,112...34,025,908
Ensembl chr 7:33,924,189...34,025,903
|
|
G |
Polm |
DNA polymerase mu |
decreases expression |
ISO |
Bortezomib results in decreased expression of POLM mRNA |
CTD |
PMID:20977926 |
|
NCBI chr14:80,707,075...80,716,677
Ensembl chr14:80,706,345...80,717,086
|
|
G |
Polr2a |
RNA polymerase II subunit A |
multiple interactions |
ISO |
Bortezomib promotes the reaction [alvocidib results in decreased phosphorylation of POLR2A protein]; Bortezomib promotes the reaction [Dichlororibofuranosylbenzimidazole results in decreased phosphorylation of POLR2A protein] |
CTD |
PMID:15039284 |
|
NCBI chr10:54,452,438...54,478,486
Ensembl chr10:54,452,441...54,478,455
|
|
G |
Polr3e |
RNA polymerase III subunit E |
increases expression |
ISO |
Bortezomib results in increased expression of POLR3E mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:175,466,091...175,494,679
Ensembl chr 1:175,466,127...175,494,667
|
|
G |
Polr3h |
RNA polymerase III subunit H |
decreases expression |
ISO |
Bortezomib results in decreased expression of POLR3H mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:113,429,434...113,439,743
Ensembl chr 7:113,429,451...113,439,778
|
|
G |
Pot1 |
protection of telomeres 1 |
decreases expression multiple interactions |
ISO |
Bortezomib results in decreased expression of POT1 mRNA; Bortezomib results in decreased expression of POT1 protein TERT protein inhibits the reaction [Bortezomib results in decreased expression of POT1 mRNA] |
CTD |
PMID:36401358 |
|
NCBI chr 4:54,205,330...54,263,137
Ensembl chr 4:54,205,332...54,263,042
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
increases response to substance |
ISO |
PPARD gene SNP results in increased susceptibility to Bortezomib |
CTD |
PMID:20864405 |
|
NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
ISO |
Bortezomib inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein] |
CTD |
PMID:30818834 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ppm1a |
protein phosphatase, Mg2+/Mn2+ dependent, 1A |
increases expression |
ISO |
Bortezomib results in increased expression of PPM1A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:91,439,094...91,486,139
Ensembl chr 6:91,438,834...91,480,697
|
|
G |
Ppm1f |
protein phosphatase, Mg2+/Mn2+ dependent, 1F |
increases expression |
ISO |
Bortezomib results in increased expression of PPM1F mRNA |
CTD |
PMID:20977926 |
|
NCBI chr11:84,064,422...84,094,410
Ensembl chr11:84,064,420...84,094,340
|
|
G |
Ppp1r15a |
protein phosphatase 1, regulatory subunit 15A |
increases expression |
ISO |
Bortezomib results in increased expression of PPP1R15A mRNA; Bortezomib results in increased expression of PPP1R15A protein |
CTD |
PMID:15509775 PMID:20022965 |
|
NCBI chr 1:96,000,053...96,003,128
Ensembl chr 1:96,000,058...96,003,171
|
|
G |
Ppp2r2a |
protein phosphatase 2, regulatory subunit B, alpha |
increases expression |
ISO |
Bortezomib results in increased expression of PPP2R2A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr15:41,204,659...41,263,924
Ensembl chr15:41,204,200...41,263,924
|
|
G |
Ppp2r5d |
protein phosphatase 2, regulatory subunit B', delta |
decreases expression |
ISO |
Bortezomib results in decreased expression of PPP2R5D mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 9:14,270,364...14,300,396
Ensembl chr 9:14,268,745...14,300,400
|
|
G |
Ppp3r1 |
protein phosphatase 3, regulatory subunit B, alpha |
decreases expression |
ISO |
Bortezomib results in decreased expression of PPP3R1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr14:91,556,743...91,606,391
Ensembl chr14:91,604,121...91,606,907
|
|
G |
Ppp5c |
protein phosphatase 5, catalytic subunit |
decreases expression |
ISO |
Bortezomib results in decreased expression of PPP5C mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:77,690,203...77,714,507
Ensembl chr 1:77,690,208...77,714,456
|
|
G |
Prdm2 |
PR/SET domain 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of PRDM2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:155,421,066...155,531,884
Ensembl chr 5:155,422,134...155,531,825
|
|
G |
Prf1 |
perforin 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of PRF1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr20:29,246,202...29,251,712
Ensembl chr20:29,246,202...29,251,701
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
multiple interactions |
ISO |
Bortezomib inhibits the reaction [geldanamycin results in decreased expression of and results in decreased phosphorylation of PRKAA1 protein] |
CTD |
PMID:37481222 |
|
NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978
|
|
G |
Prkaa2 |
protein kinase AMP-activated catalytic subunit alpha 2 |
multiple interactions |
ISO |
Bortezomib inhibits the reaction [geldanamycin results in decreased expression of and results in decreased phosphorylation of PRKAA2 protein] |
CTD |
PMID:37481222 |
|
NCBI chr 5:119,807,992...119,879,987
Ensembl chr 5:119,813,226...119,879,543
|
|
G |
Prkcd |
protein kinase C, delta |
multiple interactions |
ISO |
[arsenic trioxide co-treated with Bortezomib] results in increased cleavage of and results in increased activity of PRKCD protein; Bortezomib promotes the reaction [NSC606985 results in increased activity of and results in increased cleavage of PRKCD protein] |
CTD |
PMID:17495969 PMID:19662097 |
|
NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352
|
|
G |
Prkdc |
protein kinase, DNA-activated, catalytic subunit |
multiple interactions increases cleavage decreases expression |
ISO |
[CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of PRKDC protein]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of PRKDC protein] Bortezomib results in decreased expression of PRKDC mRNA |
CTD |
PMID:12393500 PMID:20977926 |
|
NCBI chr11:85,040,790...85,258,357
Ensembl chr11:85,040,792...85,257,952
|
|
G |
Prnp |
prion protein |
increases expression |
ISO |
Bortezomib results in increased expression of PRNP mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:119,186,073...119,201,513
Ensembl chr 3:119,177,485...119,203,937
|
|
G |
Prpf6 |
pre-mRNA processing factor 6 |
decreases expression |
ISO |
Bortezomib results in decreased expression of PRPF6 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:168,706,952...168,771,191
Ensembl chr 3:168,704,299...168,774,991
|
|
G |
Prr7 |
proline rich 7 (synaptic) |
decreases expression |
ISO |
Bortezomib results in decreased expression of PRR7 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:9,164,375...9,173,669
Ensembl chr17:9,165,269...9,172,536
|
|
G |
Psap |
prosaposin |
increases expression |
ISO |
Bortezomib results in increased expression of PSAP mRNA |
CTD |
PMID:20977926 |
|
NCBI chr20:28,214,229...28,240,501
Ensembl chr20:28,214,271...28,240,498
|
|
G |
Psen1 |
presenilin 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of PSEN1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:103,323,052...103,375,088
Ensembl chr 6:103,323,120...103,371,650
|
|
G |
Psmb5 |
proteasome 20S subunit beta 5 |
affects binding decreases response to substance increases expression affects response to substance |
ISO EXP |
Bortezomib binds to PSMB5 protein PSMB5 gene mutant form results in decreased susceptibility to Bortezomib Bortezomib results in increased expression of PSMB5 mRNA PSMB5 protein affects the susceptibility to Bortezomib |
CTD |
PMID:20213465 PMID:22216088 |
|
NCBI chr15:28,072,772...28,077,367
Ensembl chr15:28,072,781...28,077,440
|
|
G |
Psmc4 |
proteasome 26S subunit, ATPase 4 |
increases expression |
ISO |
Bortezomib results in increased expression of PSMC4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:83,349,127...83,357,497
Ensembl chr 1:83,348,592...83,357,494
|
|
G |
Psmd12 |
proteasome 26S subunit, non-ATPase 12 |
increases expression |
ISO |
Bortezomib results in increased expression of PSMD12 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:92,438,223...92,457,323
Ensembl chr10:92,438,298...92,457,287
|
|
G |
Psmd13 |
proteasome 26S subunit, non-ATPase 13 |
increases expression |
ISO |
Bortezomib results in increased expression of PSMD13 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:195,964,617...195,976,895
Ensembl chr 1:195,964,138...195,976,905
|
|
G |
Psmd7 |
proteasome 26S subunit, non-ATPase 7 |
increases expression |
ISO |
Bortezomib results in increased expression of PSMD7 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr19:35,494,317...35,501,605
Ensembl chr19:35,494,316...35,501,588
|
|
G |
Psmf1 |
proteasome inhibitor subunit 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of PSMF1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:140,235,371...140,260,546
Ensembl chr 3:140,235,373...140,260,546
|
|
G |
Ptbp1 |
polypyrimidine tract binding protein 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of PTBP1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:9,842,574...9,852,332
Ensembl chr 7:9,842,574...9,852,397
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression multiple interactions |
ISO |
Bortezomib results in increased expression of PTGS2 mRNA; Bortezomib results in increased expression of PTGS2 protein Bortezomib promotes the reaction [capillarisin results in decreased expression of PTGS2 protein]; NFKBIA protein mutant form inhibits the reaction [Bortezomib results in increased expression of PTGS2 protein] |
CTD |
PMID:21215737 PMID:24085292 PMID:24333736 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Pthlh |
parathyroid hormone-like hormone |
decreases expression |
ISO |
Bortezomib results in decreased expression of PTHLH mRNA |
CTD |
PMID:18089816 |
|
NCBI chr 4:180,188,792...180,199,847
Ensembl chr 4:180,188,792...180,199,847
|
|
G |
Ptp4a3 |
protein tyrosine phosphatase 4A3 |
decreases expression |
ISO |
Bortezomib results in decreased expression of PTP4A3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:105,650,640...105,660,921
Ensembl chr 7:105,628,029...105,660,919
|
|
G |
Ptpn11 |
protein tyrosine phosphatase, non-receptor type 11 |
decreases expression |
ISO |
Bortezomib results in decreased expression of PTPN11 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr12:35,365,436...35,424,925
Ensembl chr12:35,383,144...35,424,925
|
|
G |
Ptpn6 |
protein tyrosine phosphatase, non-receptor type 6 |
decreases expression |
ISO |
Bortezomib results in decreased expression of PTPN6 mRNA |
CTD |
PMID:17659339 |
|
NCBI chr 4:157,526,034...157,550,783
Ensembl chr 4:157,526,035...157,550,984
|
|
G |
Ptx3 |
pentraxin 3 |
decreases expression |
ISO |
Bortezomib results in decreased expression of PTX3 mRNA |
CTD |
PMID:20471514 |
|
NCBI chr 2:150,487,513...150,493,323
Ensembl chr 2:150,487,513...150,493,323
|
|
G |
R3hdm4 |
R3H domain containing 4 |
decreases expression |
ISO |
Bortezomib results in decreased expression of R3HDM4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:9,790,401...9,797,512
Ensembl chr 7:9,790,322...9,797,512
|
|
G |
Rab5a |
RAB5A, member RAS oncogene family |
decreases expression |
ISO |
Bortezomib results in decreased expression of RAB5A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 9:6,483,906...6,512,877
Ensembl chr 9:6,484,469...6,512,873
|
|
G |
Rab8b |
RAB8B, member RAS oncogene family |
decreases expression |
ISO |
Bortezomib results in decreased expression of RAB8B mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 8:67,458,921...67,536,466
Ensembl chr 8:67,458,923...67,536,384
|
|
G |
Rac2 |
Rac family small GTPase 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of RAC2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:110,101,344...110,128,718
Ensembl chr 7:110,116,260...110,128,720
|
|
G |
Rad51 |
RAD51 recombinase |
decreases expression |
ISO |
Bortezomib results in decreased expression of RAD51 mRNA |
CTD |
PMID:21917757 |
|
NCBI chr 3:106,099,753...106,125,038
Ensembl chr 3:106,100,381...106,125,035
|
|
G |
Raf1 |
Raf-1 proto-oncogene, serine/threonine kinase |
multiple interactions decreases expression |
ISO |
[Bortezomib co-treated with Butyrates] results in decreased expression of RAF1 protein; [Bortezomib co-treated with panobinostat] results in decreased expression of RAF1 protein; [Bortezomib co-treated with vorinostat] results in decreased expression of RAF1 protein Bortezomib results in decreased expression of RAF1 protein |
CTD |
PMID:12893773 PMID:18445700 |
|
NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317
|
|
G |
Rala |
RAS like proto-oncogene A |
increases expression |
ISO |
Bortezomib results in increased expression of RALA mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:47,092,163...47,145,192
Ensembl chr17:47,092,207...47,144,063
|
|
G |
Rapgef1 |
Rap guanine nucleotide exchange factor 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of RAPGEF1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:12,898,349...13,016,234
Ensembl chr 3:12,898,266...13,013,984
|
|
G |
Raph1 |
Ras association (RalGDS/AF-6) and pleckstrin homology domains 1 |
increases expression |
ISO |
Bortezomib results in increased expression of RAPH1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 9:61,907,476...61,990,170
Ensembl chr 9:61,907,758...61,961,209
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
multiple interactions increases response to substance |
ISO |
[Bortezomib co-treated with Butyrates] results in increased degradation of RB1 protein; [Bortezomib co-treated with vorinostat] results in increased degradation of RB1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased phosphorylation of RB1 protein; [RB1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein; TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased phosphorylation of RB1 protein] |
CTD |
PMID:12893773 PMID:25522274 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rb1cc1 |
RB1-inducible coiled-coil 1 |
increases expression |
ISO |
Bortezomib results in increased expression of RB1CC1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:13,161,648...13,225,560
Ensembl chr 5:13,161,648...13,225,560
|
|
G |
Rcan3 |
RCAN family member 3 |
decreases expression |
ISO |
Bortezomib results in decreased expression of RCAN3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:147,650,935...147,671,881
Ensembl chr 5:147,655,085...147,671,937
|
|
G |
Rdh11 |
retinol dehydrogenase 11 |
increases expression |
ISO |
Bortezomib results in increased expression of RDH11 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:97,979,377...97,995,252
Ensembl chr 6:97,979,378...97,995,252
|
|
G |
Rdh13 |
retinol dehydrogenase 13 |
increases expression |
ISO |
Bortezomib results in increased expression of RDH13 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:69,373,014...69,401,454
Ensembl chr 1:69,373,113...69,400,908
|
|
G |
Recql4 |
RecQ like helicase 4 |
increases expression |
ISO |
Bortezomib results in increased expression of RECQL4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:108,423,453...108,430,790
Ensembl chr 7:108,423,455...108,430,619
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions decreases expression decreases activity |
ISO |
[Bortezomib co-treated with Arsenic Trioxide] results in decreased activity of RELA protein; [Bortezomib co-treated with Doxorubicin] results in decreased phosphorylation of RELA protein; [Bortezomib co-treated with trichostatin A] results in decreased expression of and results in decreased activity of RELA protein; [Bortezomib co-treated with trichostatin A] results in decreased expression of RELA protein; [Bortezomib co-treated with Vorinostat] results in decreased activity of [NFKB1 protein binds to RELA protein]; [Resveratrol co-treated with Bortezomib] results in decreased activity of [RELA protein binds to NFKB1 protein]; Bortezomib inhibits the reaction [belinostat results in increased acetylation of RELA protein]; Bortezomib inhibits the reaction [romidepsin results in increased acetylation of RELA protein]; Bortezomib inhibits the reaction [TNF protein affects the localization of RELA protein]; Bortezomib promotes the reaction [Fenretinide inhibits the reaction [TNF protein results in increased activity of RELA protein]] Bortezomib results in decreased expression of RELA mRNA; Bortezomib results in decreased expression of RELA protein Bortezomib results in decreased activity of RELA protein |
CTD |
PMID:12893773 PMID:16230421 PMID:16904634 PMID:17164350 PMID:17626072 PMID:18223231 PMID:18593997 PMID:20471514 PMID:20977926 PMID:33775688 PMID:34861246 More...
|
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rffl |
ring finger and FYVE-like domain containing E3 ubiquitin protein ligase |
increases expression |
ISO |
Bortezomib results in increased expression of RFFL mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:67,740,711...67,803,669
Ensembl chr10:67,740,712...67,824,434
|
|
G |
Rhobtb2 |
Rho-related BTB domain containing 2 |
increases response to substance |
ISO |
RHOBTB2 gene SNP results in increased susceptibility to Bortezomib |
CTD |
PMID:20864405 |
|
NCBI chr15:44,868,251...44,888,436
Ensembl chr15:44,870,376...44,888,651
|
|
G |
Rhot2 |
ras homolog family member T2 |
decreases ex | |